Extracellular and Intracellular Regulation of G Protein-Coupled Receptor Signaling by Rittiner, Joseph
 Extracellular and Intracellular Regulation of G Protein-Coupled Receptor Signaling 
 
Joseph E. Rittiner 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the School of 
Pharmacy (Chemical Biology and Medicinal Chemistry) 
 
Chapel Hill 
2013 
        
       Approved by: 
       Alexander Tropsha 
       Mark J. Zylka 
       Stephen Frye 
       Ken McCarthy 
       T. Kendall Harden
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2013 
Joseph E. Rittiner 
ALL RIGHTS RESERVED 
iii 
 
 
ABSTRACT 
Joseph E. Rittiner:  Extracellular and Intracellular Regulation of G Protein-Coupled Receptor 
Signaling 
(Under the direction of Dr. Mark J. Zylka) 
 
 Signaling through G protein-coupled receptors (GPCRs) is an essential part of 
cellular communication, and nearly half of modern pharmaceuticals target GPCRs in some 
way.  GPCRs are also subject to extensive biological regulation, which is incompletely 
understood.  Here, I examined both extracellular metabolic control of GPCR signaling, and 
intracellular feedback mechanisms which regulate downstream signal transduction and 
receptor desensitization.  I first found that the nucleotide adenosine 5’-monophosphate 
(AMP) is an agonist of the A1 adenosine receptor.  Previously, AMP was thought to signal 
exclusively via hydrolysis to adenosine, and no AMP receptor was known to exist.  Using a 
novel real-time assay of adenosine receptor activity, I showed that AMP directly activates 
A1R independent of hydrolysis to adenosine, but that activation of the adenosine A2B receptor 
required hydrolysis to adenosine.  I also identified a histidine residue in the A1R binding 
pocket critical for receptor activation by AMP, but not adenosine.  These results suggest that 
some of the A1R-mediated physiological effects attributed to adenosine may in fact be 
directly caused by AMP.  Furthermore, I found that extracellular loop 2 partially determines 
A1R sensitivity to AMP, and that AMP stimulation elicits differential activation of signaling 
cascades downstream of A1R.  In subsequent work, I found that the novel lipid kinase 
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diacylglycerol kinase eta (DGKη) positively modulates signaling downstream of muscarinic 
and purinergic GPCRs.  This effect required DGKη catalytic activity, but only a minimal 
level of DGKη expression.  DGKη expression also suppressed extracellular signal-related 
kinase (ERK) phosphorylation downstream of protein kinase C (PKC) and both activation 
and depletion of PKC abolished the DGKη effect on GPCR signaling, indicating that DGKη 
enhances GPCR signaling by suppressing PKC activation, likely reducing receptor 
desensitization.  Enhanced expression of DGKη is linked to bipolar disorder (BPD), 
suggesting that increased DGKη activity contributes to the dysregulation of GPCR and PKC 
signaling in BPD and that DGKη inhibitors may have therapeutic potential for the treatment 
of BPD.  Together, my work expands the current understanding of adenosine receptor 
signaling, implies an enhanced role for multiple endogenous ligands and functional 
selectivity in physiological GPCR signaling, and highlights GPCR-modulating enzymes as 
targets for drug discovery. 
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CHAPTER 1:  A BRIEF INTRODUCTION TO GPCR SIGNALING 
 
 G protein-coupled receptors (GPCRs) are a fundamental part of cellular 
communication in all eukaryotic organisms.  Indeed, the importance of GPCRs in biological 
signaling is difficult to overstate; they are responsible for an estimated 80% of all signal 
transduction across biological membranes (1).  Furthermore, GPCRs are highly druggable 
proteins, and are an essential component of modern pharmacology.  As of 2013, over 30% of 
the small-molecule drugs currently on the market target GPCRs in some fashion (2).  As 
such, a thorough understanding of GPCR structure and function is crucial both in the 
investigation of biological signaling processes and in future drug discovery.  As recognition 
of the importance of GPCR signaling, multiple researchers have received Nobel Prizes in 
Chemistry or Medicine for work on GPCR signaling, including Alfred Gilman and Martin 
Rodbell in 1994 for the discovery of G proteins, Richard Axel and Linda Buck in 2004 for 
the characterization of olfactory receptors, and Brian Kobilka and Robert Lefkowitz in 2012 
for work examining the structure and signaling mechanisms of GPCRs. 
 GPCRs span the cellular plasma membrane, and a significant portion of a given 
GPCR exists within the interior of the lipid bilayer.  As such, detailed information regarding 
GPCR structure was unavailable for many years, as their amphiphilic composition – which is 
stabilized by the lipid bilayer, but not stable in aqueous solution – makes GPCR 
crystallization extremely difficult.  However, high resolution crystal structures of multiple 
GPCRs including rhodopsin (3-5), the β2 adrenergic receptor (6-8), and the A2A adenosine 
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receptor (9-11) have now been solved, providing a more complete understanding of GPCR 
structure and function. 
 The core structural component of all GPCRs is a series of 7 transmembrane α-helices, 
arranged in a roughly cylindrical bundle.  These helices are traditionally numbered I-VII, in 
order from N- to C-terminus.  The N-terminus of GPCRs is always located on the 
extracellular side of the plasma membrane, and is often heavily N-glycosylated; this complex 
glycosylation is required for proper expression and trafficking of GPCRs (12).  Conversely, 
the C-terminus is located on the intracellular face of the plasma membrane, and is important 
for interactions with scaffolding and regulatory proteins.  The proximal portion of the C-
terminus consists of another α-helix (helix VIII) oriented parallel to the plasma membrane 
and anchored by palmitoylation of one or more conserved cysteine residues (13,14). 
 The transmembrane helices are connected by three extracellular and three 
intracellular loops (EL1-EL3 and IL1-IL3, respectively).  Of the extracellular loops, EL2 is 
of particular interest, as it is stabilized by a highly-conserved disulfide bond with the 
extracellular end of helix III (15), and is often located in close proximity to the ligand 
binding site (16).  Of the intracellular loops, IL2 and IL3 are the most noteworthy, as they 
constitute a significant portion of the G protein coupling interface.  Furthermore, IL2 is 
anchored by a very highly conserved E/DRY series of residues at the cytoplasmic end of 
helix III, which is believed to be involved in stabilizing receptor conformational states (17).  
In the vast majority of GPCRs, the ligand binding pocket is located between the extracellular 
ends of the transmembrane helices, within the plasma membrane.  However, the members of 
a small subfamily, the class C GPCRs, have a large N-terminal ligand binding domain that 
extends into the extracellular space (18). 
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 GPCRs signal primarily through interactions with heterotrimeric G proteins.  As 
implied by the name, heterotrimeric G proteins are composed of three subunits, α (alpha), β 
(beta), and γ (gamma).  The Gα subunits are homologous to the Ras family of small GTPase 
signaling proteins (19), and function in a similar fashion.  However, unlike small GTPases, 
Gα subunits are tethered to the plasma membrane by N-terminal myristoylation and/or 
palmitoylation (20).  In their inactive state, Gα subunits bind a molecule of guanosine 
diphosphate (GDP), and form a complex with Gβ, Gγ, and a coupled GPCR.  Upon ligand 
binding, GPCRs undergo a conformational change which causes the release of GDP from the 
coupled Gα subunit, where it is replaced by a molecule of guanosine triphosphate (GTP) 
from the cytosol.  The precise characteristics of this conformational change have only 
recently begun to be elucidated.  As currently understood, agonist binding causes an outward 
motion in the cytoplasmic ends of transmembrane helices V and VI, creating a cavity into 
which the C-terminus of the coupled Gα subunit extends (8,21). 
 GTP binding causes a conformational change in Gα, which results in the dissociation 
of the Gα subunit from the coupled GPCR and the other G protein subunits.  In their active, 
GTP-bound state, Gα subunits diffuse freely throughout the plasma membrane, where they 
interact with and activate various membrane-bound second messenger proteins (Fig. 1.1).  G 
protein signaling is terminated by the enzymatic hydrolysis of Gα-bound GTP into GDP, 
which causes the Gα subunit to revert back to its inactive conformation and re-associate with 
the β and γ subunits of the heterotrimeric G protein complex (22).  In isolation, Gα subunits 
catalyze GTP hydrolysis very poorly.  However, signal termination is facilitated by a large 
family of regulator of G protein signaling (RGS) proteins, which greatly enhance the rate of 
GTP hydrolysis through interactions with active Gα subunits (23).
 4 
Figure 1.1 
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Figure 1.1.  Selected signaling pathways downstream of GPCR activation. 
 GPCR = G protein-coupled receptor.  Gαs = Gs-family alpha subunit.  Gαi = Gi-
family alpha subunit.  Gαq = Gq-family alpha subunit.  Gβγ = G protein free beta-gamma 
complex.  AC = adenylyl cyclase.  PDE = phosphodiesterase.  cAMP = 3’-5’-cyclic 
adenosine monophosphate.  PKA = protein kinase A.  PLC = phospholipase C.  DAG = 
diacylglycerol.  IP3 = inositol-1,4,5-triphosphate.  Ca
2+
 = calcium ion.  CaM = calmodulin.  
PKC = protein kinase C.  GRK = G protein-coupled receptor kinase.  GIRK = G protein-
coupled inward-rectifying potassium channel.  K
+
 = potassium ion.  PLA2 = phospholipase 
A2.  AA = arachidonic acid.  βarr = β-arrestin.  Raf = Raf kinase.  MEK = mitogen-activated 
protein kinase/ERK kinase.  ERK = extracellular signal-related kinase.  Normal arrow, 
activation/enzymatic production.  Flat arrow, inhibition/enzymatic degradation.  Red, GPCR 
phosphorylation.  Blue, phosphorylation-dependant β-arrestin interaction.
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 Numerous downstream signaling pathways can be activated after stimulation of a 
given GPCR, determined mainly by the type of Gα subunit coupled to the receptor (Fig. 1.1).  
The Gα subunits of heterotrimeric G proteins are grouped into 4 main families, Gs, Gi, Gq, 
and G12, based on sequence homology and signaling activity (24).  Of these, the Gs and Gi 
families signal primarily by modulating intracellular levels of cyclic adenosine 
monophosphate (cAMP).  The Gs (stimulatory) family contains two members: Gαs, which is 
ubiquitously expressed, and Gαolf, which is exclusively expressed in the olfactory system and 
is responsible for signal transduction through the large olfactory subfamily of GCPRs (25).  
Activation of Gs-family Gα subunits leads to stimulation of adenylyl cyclase (AC), which 
converts ATP into cAMP, raising intracellular concentrations of cAMP (Fig. 1.1).  Elevated 
cyclic AMP leads to the activation of protein kinase A (PKA), which phosphorylates multiple 
downstream effectors. 
 The Gi (inhibitory) family contains 5 members: Gαi, Gαo, Gαz, Gαt (transducin), and 
Gαgust (gustducin).  While the Gαi, Gαo, and Gαz subunits are widely expressed, transducin is 
exclusively expressed in the vision system, and couples to the light sensitive GPCRs 
rhodopsin and the three cone opsins (26).  Similarly, gustducin is exclusively expressed in 
the taste and gastrointestinal systems (27,28).  Activation of Gi-family Gα subunits leads to 
inhibition of adenylyl cyclase and the stimulation of phosphodiesterase (PDE) enzymes 
which hydrolyze cAMP (Fig. 1.1).  Both of these activities decrease intracellular levels of 
cAMP, leading to a suppression of PKA activity and its associated downstream effectors.  
Activation of transducin more specifically results in the stimulation of a cyclic guanosine 
monophosphate (cGMP)-specific phosphodiesterase, leading to the closing of cGMP-gated 
cation channels, a critical step in visual signal transduction (29). 
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 The Gq family contains 5 members: Gαq, Gα11, Gα14, Gα15, and Gα16.  The Gq family 
transduces signals using an entirely different second messenger system than the Gs and Gi 
families (Fig. 1.1).  Activation of Gq-family Gα subunits leads to the stimulation of 
phospholipase C (PLC), which catalyses the hydrolysis of phosphatidylinositol-4,5-
bisphosphate (PIP2) into inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG).  IP3 
activates IP3 receptors on the endoplasmic reticulum, leading to the release of intracellular 
calcium stores and an increase in cytosolic calcium concentration.  DAG activates 
conventional and novel isoforms of protein kinase C (PKC), leading to the phosphorylation 
of multiple downstream effectors (30), including MAP kinase cascades which culminate in 
the phosphorylation and activation of extracellular signal-related kinase (ERK).  Elevated 
calcium also activates multiple downstream effectors, including conventional isoforms of 
PKC (30) and calmodulin-regulated proteins (31). 
 The G12 family contains two members: Gα12 and Gα13.  The G12 family signals 
primarily via downstream activation of the Rho family of GTPases (32), and is poorly 
understood compared to the Gs, Gi, and Gq families.  All GPCRs identified thus far that 
couple to the G12 family also couple to one of the other Gα families (32), suggesting that 
G12 may function in a secondary signaling role (G12 not shown in Fig. 1.1). 
 The GPCR-coupling selectivity of Gα subunits is primarily determined by the 
extreme C-terminal 5 amino acids (33,34), which extend into a cavity formed between the 
intracellular ends of the GPCR transmembrane helices upon receptor activation (8).  
However, the structural determinants of Gα-coupling selectivity of GPCRs are more 
complex, broadly encompassing the intracellular loops, intracellular regions of the 
transmembrane helices, and the proximal portion of the C-terminus.  Most GPCRs 
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preferentially couple to a single Gα family, but many GPCRs can couple to multiple Gα 
families under certain circumstances.  For example, Gα-coupling selectivity (and binding to 
other intracellular proteins) in a single activated GPCR can be directed by the structure of the 
activating agonist, a phenomenon known as functional selectivity (35).  GPCR coupling 
selectivity can also be influenced by dimerization or oligomerization of the receptor (36). 
 The other two members of the heterotrimeric G protein complex, Gβ (beta) and Gγ 
(gamma), form an obligate dimer and as such are usually referred to together as the G beta-
gamma complex, or simply Gβγ.  There are currently 5 known isoforms of Gβ, and 11 known 
isoforms of Gγ (37), which can form numerous combination of Gβγ pairs with different 
signaling properties (38).  Gβγ is tethered to the plasma membrane by farnesylation or 
geranylgeranylation of the C-terminus of Gγ (20), and binds the inactive, GDP-bound state of 
Gα subunits.  Upon guanine nucleotide exchange, Gβγ is released from Gα; free Gβγ diffuses 
along the plasma membrane and activates downstream effectors independently of Gα.  The 
signaling roles of free Gβγ are poorly understood, at least compared to the current 
understanding of Gα signaling.  The most well-characterized activity of free Gβγ is gating the 
opening of G protein coupled inward rectifying potassium channels (GIRKs) (39).  However, 
free Gβγ can also activate PLC (40,41), and phospholipase A2 (42), among other 
downstream effectors (Fig. 1.1). 
 After activation, GPCRs are phosphorylated by downstream effector kinases at 
multiple locations on the intracellular loops and C-terminus (Fig 1.1, red).  GPCRs are 
directly phosphorylated by both PKA (43) and PKC (44), as well as by G protein-coupled 
receptor kinases (GRKs), which are themselves activated by Gβγ, PKA, and PKC (45,46).  
This feedback mechanism can have multiple effects on GPCR function, with the particular 
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fate of receptor signaling depending on the pattern of phosphorylation and the specific 
receptor (47).  Among these regulatory effects, GPCR phosphorylation can directly and 
indirectly cause uncoupling of the GPCR from Gα subunits, leading to a termination of 
signaling downstream of GPCR activation (48), a process known as desensitization.  In some 
cases, GPCR phosphorylation may also modify receptor ability to couple to different Gα 
subunits (49), effectively redirecting GPCR signaling to different downstream pathways (50), 
though this is somewhat controversial (51).  Lastly, and perhaps most importantly, GPCR 
phosphorylation promotes the recruitment of β-arrestin proteins to activated GPCRs (Fig. 
1.1, blue), which has multiple signaling functions. 
 β-arrestin binding to GPCRs occludes the interface required for Gα subunit coupling, 
leading to receptor uncoupling and desensitization (52).  Additionally, β-arrestin acts as a 
scaffolding protein, recruiting proteins required for endocytosis, such as clathrin (53) and 
AP-2 (54), to the GPCR signaling complex.  As such, β-arrestin is important in both short-
term (receptor desensitization by disruption of G protein coupling) and long-term (receptor 
internalization through endocytosis) negative regulation of receptor activity.  β-arrestins can 
also recruit enzymes which terminate second messenger signaling downstream of GPCR 
activation.  For example, β-arrestins recruit PDEs (which hydrolyze the second messenger 
cAMP) downstream of Gαs signaling (55), and diacylglycerol kinases (which phosphorylate 
the second messenger DAG) downstream of Gαq signaling (56).  Lastly, β-Arrestin 
recruitment actually stimulates other downstream signaling pathways, such as MAP kinase 
cascades leading to ERK phosphorylation (Fig. 1.1) (57). 
 In addition to β-arrestins, GPCRs interact with numerous other scaffolding and 
accessory proteins, including ion channels, 14-3-3 proteins, PDZ-domain proteins, A-kinase 
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anchoring proteins, and others (58).  Apart from the regulation of GPCR signaling itself, 
these associations are important for receptor trafficking, localization, and cytoskeletal 
anchoring in lipid rafts and signaling complexes (58,59).  As partially detailed in Figure 1.1, 
which presents only a very limited view, GPCRs can influence a staggering number of 
intracellular signaling pathways.  The what, when, and where of these downstream signaling 
events, and thus their integration into biological signaling networks, is subject to very 
complex and detailed regulation, about which we understand very little.  Indeed, given the 
tremendous importance of GPCRs in nearly every type of extracellular and intracellular 
signaling, the current scientific understanding of GPCR signaling and regulation is 
incomplete at best.  As such, further efforts to characterize the endogenous regulation of 
GPCR signaling are of the utmost importance in developing a better understanding of the 
molecular bases of normal biological signaling.  However, a better understanding of the role 
of GPCRs in abnormal biological signaling is even more critical, given the enormous 
potential – both past and future – of GPCRs as targets for therapeutic drug discovery. 
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CHAPTER 2:  THE NUCLEOTIDE AMP IS AN ADENOSINE A1 RECEPTOR 
AGONIST 
 
INTRODUCTION 
 Adenosine and adenine nucleotides regulate diverse physiological processes (60,61).  
Adenosine activates four distinct G protein-coupled receptors, the so called P1 purinergic 
receptors:  adenosine A1 receptor (A1R, ADORA1), adenosine A2A receptor (A2AR, 
ADORA2A), adenosine A2B receptor (A2BR, ADORA2B), and adenosine A3 receptor (A3R, 
ADORA3).  A1R and A3R are Gi/o-coupled and inhibit adenylate cyclase when activated 
while A2AR and A2BR are Gs-coupled and stimulate adenylate cyclase.   
 While mammals have numerous P2 purinergic receptors for ATP and ADP, no 
receptor for their hydrolysis product (AMP) has been definitively identified.  GPR80/GPR99 
was originally classified as an adenosine and AMP receptor (62), however this finding has 
now been discounted (63,64).  AMP has diverse physiological effects, suggesting a receptor 
for AMP could exist (65-74).   
 Complicating studies with AMP is the fact that cells express multiple enzymes that 
hydrolyze extracellular AMP to adenosine, including ecto-5’-nucleotidase (NT5E, CD73), 
Prostatic acid phosphatase (PAP, ACPP) and several alkaline phosphatases (75-78).  Genetic 
deletion or pharmacological inhibition of individual ectonucleotidases reduces, but does not 
always eliminate, the physiological effects of AMP (65,67,70,72,79).  And, the most 
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commonly used ectonucleotidase inhibitor α,β-methylene-ADP (αβ-met-ADP) inhibits 
NT5E, but it does not inhibit PAP (70).   
 Many of the physiological effects of AMP are lost in A1R knockout mice or can be 
blocked with adenosine receptor antagonists (65,67,70,72-74), suggesting adenosine is the 
active ligand.  However, given the challenges associated with inhibiting all ectonucleotidases 
in complex tissues (79), direct activation of adenosine receptors by AMP cannot be so easily 
ruled out.   
 Extracellular AMP originates from multiple endogenous sources (75), and nucleotide 
release and hydrolysis can be rapid (79,80).  Endogenous AMP could thus directly modulate 
diverse adenosine-receptor dependent processes, including cardiovascular disease, cancer, 
neurotransmission and gliotransmission (60,61,81-83). 
 To rigorously study direct and indirect effects of AMP on adenosine receptors, we 
developed a novel cell based assay utilizing chimeric G proteins to visualize human (h)A1R 
and hA2BR activation in real-time and at single cell resolution.  We also used a non-
hydrolyzable AMP analog to rule out the effects of AMP hydrolysis.  Surprisingly, we found 
that AMP directly activated hA1R, but not hA2BR, and activation was independent of 
hydrolysis to adenosine.  Our study thus indicates that A1R is a receptor for the naturally 
occurring nucleotide AMP as well as a receptor for adenosine. 
 13 
MATERIALS AND METHODS 
Materials 
 Adenosine (A9251), AMP (01930), inosine (I4125), 2-chloro-N
6
-
cyclopentyladenosine (C7938), N
6
-cyclopentyladenosine (C8031), α,β-methylene adenosine 
5’-diphosphate (αβ-met-ADP; M3763), and pertussis toxin (P7208) were purchased from 
Sigma-Aldrich.  Pyridoxalphosphate-6-azophenyl-2’,4’-disulfonic acid (PPADS; 0625) and 
suramin (1472) were purchased from Tocris Bioscience.  Stock solutions of adenosine (10 
mM), AMP (10 mM), αβ-met-ADP (50 µM), PPADS (10 mM), and suramin (10 mM) were 
made in Hank’s balanced salt solution assay buffer (HBSS, Gibco catalog #14025, 
supplemented with 9 mM HEPES, 11 mM D-glucose, 0.1% fatty-acid free bovine serum 
albumin, pH 7.3) and frozen at -80°C in single use aliquots.  All other compounds were 
dissolved in HBSS assay buffer at final concentration immediately before use.  
 
Molecular Biology 
 Full-length expression constructs for human A1R (GenBank accession #AY136746) 
and human A2BR (GenBank accession #AY136748) were obtained from the Missouri S&T 
Clone Collection (www.cdna.org).  Human A1R point mutants were generated by PCR-based 
mutagenesis.  Chimeric G protein constructs (Gαq-i5 and Gαq-s5) and the mouse 
transmembrane (TM)-PAP (nt 64-1317 from GenBank accession # NM_207668) expression 
construct were previously described (76,84,85).  Full-length expression constructs of mouse 
NT5E (nt 47-1777 from GenBank accession # NM_011851.3) and mouse A1R (nt 1070-2053 
from GenBank accession # NM_001008533) were generated by RT-PCR using C57BL/6 
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dorsal root ganglia cDNA as template.  The TM-PAP and NT5E expression constructs 
hydrolyzed AMP when transfected into HEK293 cells (assessed using enzyme 
histochemistry; data not shown for NT5E and previously shown for TM-PAP (76)).  PCR-
generated constructs have a Kozak consensus sequence, were cloned into pcDNA3.1(+) and 
were sequence verified.     
 
Calcium Imaging 
 HEK293 cells were grown on polylysine-coated glass bottom culture dishes (MatTek 
Corp, P35G-0-10-C) in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% 
Fetal Bovine Serum, 100 U/mL penicillin and 100 g/mL streptomycin.  Cells were 
transfected with Lipofectamine Plus (Invitrogen) in DMEM containing 1% Fetal Bovine 
Serum, which was replaced with fresh growth media after 4 hours.  The total amount of DNA 
per transfection was adjusted to 1 µg by adding pcDNA 3.1(+).  100 ng of pCS-Venus was 
included in each transfection to identify transfected cells.  Following transfection (~24 
hours), cells were washed two times in Hank’s balanced salt solution assay buffer (HBSS, 
Gibco catalog #14025, supplemented with 9 mM HEPES, 11 mM D-glucose, 0.1% fatty-acid 
free bovine serum albumin, pH 7.3), then loaded for one hour at room temperature with 2 µM 
Fura-2 AM (Invitrogen, F-1221) and 0.02% Pluronic F-127 (Invitrogen, P3000-MP) in assay 
buffer.  Cells were washed three times with assay buffer, incubated for 30 minutes at room 
temperature, and were imaged on a Nikon Eclipse Ti microscope. 
 A Sutter DG-4 light source (excitation 340 nm / 380 nm; emission 510 nm) and 
Andor Clara CCD camera were used to image calcium responses.  Assay buffer was 
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refreshed immediately prior to imaging.  Antagonists were added in assay buffer 3 minutes 
prior to imaging.  Starting solution was aspirated and agonist solution added after 40 seconds 
of baseline imaging.  We manually pipetted and aspirated solutions for all calcium imaging 
experiments.  Only cells which expressed visible Venus protein, did not saturate the camera 
at a 40 ms exposure time, and had low (< 0.6) baseline Fura-2 ratios were analyzed.  500 ms 
excitation at 340 nm and 250 ms excitation at 380 nm were used for all experiments.                    
 Calcium responses were analyzed in two ways.  To create real-time response profiles, 
the Fura-2 fluorescence intensity ratio (340 nm/380 nm) at each time point was averaged 
over all transfected cells in each condition and then normalized relative to the average 
baseline fluorescence ratio before agonist addition.  Calcium responses were also quantified 
by calculating the area under the curve (AUC) extending 1 minute from agonist addition, 
relative to the baseline fluorescence ratio, on a cell-by-cell basis.  AUC values were then 
averaged over all cells in each condition.  Calcium response profiles and AUC data are 
presented as mean ± s.e.m.  To create dose response curves, GraphPad Prism was used to fit 
a variable slope dose response equation to the average AUC values for each agonist 
concentration. 
 
Cyclic AMP GloSensor Assay 
 Cyclic AMP determinations were made using a modified GloSensor luciferase 
detection system (Promega).  Low passage, subconfluent HEK293T cells (ATCC CRL-
11268) grown in DMEM without phenol red (Gibco #31053) and supplemented with 10% 
Fetal Bovine Serum (Gibco #26140) were reverse transfected by spotting a calcium 
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phosphate DNA complex mixture containing 12.5 ng each of GloSensor 22F plasmid 
(Promega #E2301) and human A1R plasmid in 25 mM HEPES at pH 7.1, 140 mM sodium 
chloride, 0.75 mM disodium monophosphate and 250 mM calcium chloride.  Cells were 
immediately added at a density of 20,000 cells per well using a Multidrop 384 (Titertek) to 
384 well white, clear bottom tissue culture plates (Corning #3707).  Cell plates were 
incubated for 24 hours at 37
o
C and 5% CO2.  Sixteen point, 1:3 dilutions curves of test 
compounds starting at 100 µM final concentration were diluted to 4x final concentration in 
HBSS (Gibco #14175) supplemented with 2 mM HEPES, pH 7.5 and then added to the cell 
plates with a Multimek automated liquid handling device (Nanoscreen, Charleston, SC).  
Following a 10 minute incubation at room temperature, 50 µM 3-isobutyl-1-methylxanthine 
(Sigma) and 175 nM (-)-isoproterenol hydrochloride (Sigma) were added by Multimek.  
Seven minutes later, GloSensor cAMP reagent (Promega #E1291) containing 2% luciferin 
and supplemented with 0.2% NP40 (Tergitol, Sigma) to permeabilize the cells was added by 
Multimek along with a final 5 µL addition of 100% Ethanol (Decon Labs) to eliminate 
bubbles.  Luminescence was read on an Envision plate reader (Perkin Elmer) for 15 minutes.  
Data from 95% of Vmax for isoproterenol (~10 minutes post GloSensor reagent addition) 
were normalized for scale to 100% response equivalent to the response of 1 µM 2-chloro-N
6
-
cyclopentyladenosine and 0% response equal to the response from the isoproterenol alone.  
 
Cortical Neuron Dissociation and Culture 
 Embryonic cortical neurons were cultured as previously described (86).  Briefly, 
cortices from ~E16.5 embryos were dissected and digested in dissociation medium (DM) (98 
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mM Na2SO4, 30 mM K2SO4, 5.8 mM MgCl2, 0.25 mM CaCl2, 1 mM HEPES, 20 mM D-
glucose, 0.125 mN NaOH, and 0.001% phenol red) containing 0.32 mg/mL L-cysteine 
(Sigma, W326305) and 20 U/mL papain (Roche, 10108014001) at 37°C for 20 minutes with 
occasional mixing.  After digestion, cortices were washed twice with DM containing 1 
mg/mL BSA (Sigma, A3912) and 1 mg/mL trypsin inhibitor (Sigma, T9128), followed by 
incubation in DM containing 10 mg/mL BSA and 10 mg/mL trypsin inhibitor for 2 minutes.  
Prepared cortices were then suspended in plating media (Neurobasal-A, Gibco, 10888) 
containing 4.5% FBS, 2% B27 (Gibco, 17504), 100 U/mL penicillin, 100 µg/mL 
streptomycin, and 2 mM L-glutamine) and gently disrupted by pipetting 15-20 times.  The 
dissociated neurons were counted in a hemocytometer and plated at 1 x 10
6
 cells/well in 
polylysine/laminin-coated 6-well plates containing plating media.   
 
Neuron Treatment and cAMP ELISA Assay 
 After 1 day in vitro, neuron plating media was replaced with serum-free plating media 
(otherwise identical) for 1 hour.  Afterwards, the media was replaced with Neurobasal-A 
containing 1 mM ACP or 1 µM N
6
-cyclopentyladenosine (CPA) (Sigma, C8031) for 30 
minutes.  For untreated conditions, media was replaced with Neurobasal-A containing no 
additives.  For antagonist conditions, 100 µM 8-cyclopentyl-1,3-dipropylxanthine (CPX) 
(Tocris, 0439) was added 15 minutes before agonist addition, and agonist solutions also 
contained 100 µM CPX.  Following incubation, forskolin (Sigma, F6886) was added, to a 
final concentration of 10 µM.  After a final 15 minute incubation, the media was aspirated, 
and the neurons were washed twice in ice-cold Dulbecco’s phosphate buffered saline (PBS) 
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(Sigma, D8537).  Then, lysis buffer (provided with cAMP ELISA Kit) (R&D Systems, 
KGE002B) was added, and the neurons were scraped and collected. 
 The cAMP ELISA assay was performed according to manufacturer’s instructions.  
Briefly, cells were subjected to 2 freeze/thaw cycles from -20°C to room temperature to 
ensure cell lysis.  Cells were then centrifuged at 600 x g for 10 minutes and the supernatant 
was isolated.  Neuron samples and cAMP standards were added to a microplate containing 
immobilized cAMP antibody, followed by a labeled cAMP conjugate.  After incubation and 
washes, a substrate solution was added, causing a colorimetric reaction proportional to the 
quantity of bound cAMP conjugate.  After incubation, stop solution was added, and 
absorbance was measured on a BioTek Synergy HT plate reader.  Standard curve fitting and 
sample analysis was performed using GraphPad Prism. 
  
Immunohistochemistry 
  HEK293 cells were grown on poly-D-lysine (Sigma, P0899)-coated coverslips and 
transfected using Lipofectamine Plus with 1 µg (per coverslip) of wild-type or mutant hA1R.  
24 hours after transfection, the cells were washed twice with PBS and fixed for 15 minutes 
with 4% paraformaldehyde in PBS.   The cells were then washed 3 times with PBS for 5 
minutes and permeablized with 0.05% Triton-X-100 (Fisher, BP151) in PBS for 20 minutes.  
The cells were washed three times (5 minutes/wash) and blocked with 5% normal goat serum 
(NGS) in PBS for 30 minutes.  Cells were then incubated with a 1:250 dilution of rabbit anti-
hA1R primary antibody (Santa Cruz Biotechnology, sc-28995) in 10% NGS for 2 hours, and 
washed three times (10 minutes/wash) with 10% NGS.  The cells were then incubated in the 
 19 
dark for 1 hour with a 1:1000 dilution of Alexa 546-conjugated Goat anti-rabbit secondary 
antibody (Invitrogen, A11010) in 10% NGS.  Cells were washed three times with PBS and 
mounted on glass slides.  The following day, the slides were imaged on an Olympus FV1000 
confocal microscope.  Dissociated cortical neurons were immunostained for mA1R in the 
same way, except that incubation with primary antibody was conducted at 4°C overnight.
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RESULTS 
Chimeric G proteins can be used to visualize adenosine receptor activation in real time 
 Activation of Gi-coupled A1R or Gs-coupled A2BR is typically quantified by 
measuring ligand-evoked decreases or increases in intracellular cAMP, respectively.  
However, these assays entail lysing cells at different times post-stimulation, hence these 
assays have limited temporal resolution and no cellular resolution.  In an effort to develop a 
real-time readout of adenosine receptor activation, we co-transfected HEK293 cells with 
vectors encoding hA1R and Gαq-i5 (Gqi), a chimeric G protein that couples Gi-coupled 
receptors to phospholipase C (PLC) activation and calcium mobilization (Fig. 2.1) (85).  In 
parallel, we co-transfected HEK293 cells with vectors encoding hA2BR and chimeric Gαq-s5 
(Gqs), to couple hA2BR to PLC and calcium mobilization (Fig. 2.1) (84).  As controls, we 
found that adenosine (1 mM) did not evoke calcium mobilization in untransfected HEK293 
cells or in cells expressing hA1R alone, hA2BR alone, Gqi alone or Gqs alone.  However, a 
saturating concentration of adenosine (1 mM) evoked rapid onset calcium responses that 
slowly decayed in cells co-expressing hA1R + Gqi or hA2BR + Gqs (Fig. 2.2 A,B), indicating 
adenosine receptor activation can be monitored in real-time at cellular resolution.
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Figure 2.1 
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Figure 2.1.  Real-time visualization of adenosine receptor activation and 
ectonucleotidase activity. 
 Gi-coupled A1R and Gs-coupled A2BR do not mobilize intracellular calcium when 
activated in most cell types, including HEK293 cells.  However, when A1R or A2BR are co-
expressed with chimeric G proteins that couple to phospholipase C (PLC; Gqi, Gqs, 
respectively), receptor stimulation can be visualized in real-time using the calcium-sensitive 
dye Fura-2.  PAP and NT5E hydrolyze extracellular AMP to adenosine.  Real-time 
visualization allowed us to show that (1) AMP directly activates A1R whereas (2) AMP 
activates A2BR indirectly via ectonucleotidase-catalyzed hydrolysis to adenosine.
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AMP activates hA1R independent of ectonucleotidases whereas hA2BR activation is 
ectonucleotidase-dependent 
 Since no AMP receptors have been definitively identified, we next hypothesized that 
AMP would only mobilize calcium in adenosine receptor-expressing cells after hydrolysis to 
adenosine by PAP or NT5E ectonucleotidases (Fig. 2.1).  To test this hypothesis, we co-
transfected cells with hA1R + Gqi vectors along with the membrane-bound ectonucleotidases 
PAP or NT5E.  These ectonucleotidases were enzymatically active when expressed in 
HEK293 cells (see Materials and Methods).  To our initial surprise, 1 mM AMP evoked 
calcium responses in hA1R + Gqi-expressing cells that were indistinguishable in onset and 
magnitude from calcium responses evoked by 1 mM adenosine, and co-expression of PAP or 
NT5E did not modify AMP-evoked responses (Fig. 2.2A).  Similar results were observed in 
cells co-expressing mouse A1R + Gqi (Fig. 2.3).  These AMP-evoked calcium responses 
were dependent on overexpressed A1R as AMP had no effect in HEK293 cells when Gqi was 
expressed alone (Fig. 2.2A, Fig. 2.3).  Rapid activation of A1R was not due to contaminating 
levels of adenosine (adenosine was undetectable in our AMP stock solution based on high 
performance liquid chromatography analysis).  Instead, our data suggested that a nucleotide 
(AMP) could directly activate the adenosine A1 receptor. 
 In contrast, adenosine (Fig. 2.2B, grey) and AMP (Fig. 2.2B, blue) evoked kinetically 
distinct calcium responses in hA2BR + Gqs co-expressing HEK293 cells.  Specifically, 
adenosine evoked a rapid onset calcium response that peaked shortly after agonist addition, 
while AMP elicited a gradual calcium response that began approximately 15 seconds after 
agonist addition.  Co-expression of PAP or NT5E significantly augmented the speed and 
magnitude of the AMP response (Fig. 2.2B, green, purple), suggesting these enzymes 
 24 
accelerated hydrolysis of AMP to adenosine.  Although HEK293 cells endogenously express 
hA2BR (62,87), AMP did not evoke calcium responses in cells expressing Gqs alone (Fig. 
2.2B, black).  Taken together, these data suggest that AMP only activates hA2BR indirectly 
following hydrolysis to adenosine.   
 To directly test if AMP activates hA1R or hA2BR as a result of ectonucleotidase 
activity, we repeated our experiments in the presence of α,β-methylene-ADP (αβ-met-ADP), 
a high-potency (Ki = 5 nM) NT5E inhibitor (88).  We found that αβ-met-ADP did not inhibit 
adenosine- or AMP-evoked calcium responses in cells co-expressing hA1R + Gqi (with or 
without overexpressed ectonucleotidases) (Compare Fig. 2.2A to Fig. 2.2C), further 
suggesting that AMP stimulates hA1R directly.  In contrast, 10 µM αβ-met-ADP completely 
inhibited the calcium response caused by AMP in hA2BR + Gqs-expressing cells (Fig. 2.2D, 
blue) but did not inhibit the adenosine-evoked calcium response (Fig. 2.2D, grey).  αβ-met-
ADP also significantly reduced the calcium response caused by AMP in NT5E co-expressing 
cells (Fig. 2.2D, purple) and marginally inhibited the calcium response caused by AMP in 
PAP co-expressing cells (Fig. 2.2D, green).
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Figure 2.2 
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Figure 2.2.  AMP directly activates hA1R whereas AMP activates hA2BR indirectly via 
ectonucleotidase-catalyzed hydrolysis to adenosine. 
 Calcium mobilization responses in HEK293 cells expressing (A, C) Gqi ± hA1R or 
(B, D) Gqs ± hA2BR.  (C, D)  Cells were incubated with the competitive NT5E inhibitor αβ-
met-ADP (10 µM) for 3 minutes and then were stimulated with 1 mM agonist in the presence 
of 10 µM αβ-met-ADP.  (Black) 1 mM AMP in the absence of a transfected adenosine 
receptor, but in the presence of the respective chimeric G protein.  Area under curve (AUC) 
measurements extended for 1 minute from agonist addition.  Paired t tests were used to 
compare AUC data.  Black asterisks, statistically significant difference compared to 
adenosine stimulation.  Blue asterisks, statistically significant difference compared to AMP 
stimulation (in receptor-expressing cells).  *, p < 0.05; **, p < 0.005; ***, p < 0.0005.  All 
data are the average of two experiments performed in duplicate.  n = 20-74 cells per 
condition.  All data, including calcium traces, are presented as means ± standard error.
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Figure 2.3.  AMP activates mouse A1R. 
 Calcium mobilization responses in HEK293 cells expressing Gqi ± mA1R.  Agonists:  
(Grey) 1 mM adenosine.  (Blue) 1 mM AMP.  (Green) 1 mM AMP in PAP co-expressing 
cells.  (Purple) 1 mM AMP in NT5E co-expressing cells.  (Black) 1 mM AMP in the absence 
of a transfected adenosine receptor, but in the presence of Gqi.  Area under curve (AUC) 
measurements extended for 1 minute from agonist addition.  Paired t tests were used to 
compare AUC data.  Black asterisks, significant difference compared to adenosine 
stimulation.  Blue asterisks, significant difference compared to AMP stimulation (in A1R-
expressing cells).  ***, p < 0.0005.  All data are the average of three experiments.  n = 18-34 
cells per condition.  All data, including calcium traces, are presented as means ± standard 
error.
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A non-hydrolyzable AMP analog activates hA1R but not hA2BR 
 We next sought to determine if 5’-deoxyadenosine monophosphonate (ACP), a non-
hydrolyzable analog of AMP (88), could also activate hA1R (Fig. 2.4 A,B).  We found that 1 
mM ACP evoked a rapid onset calcium response in hA1R + Gqi-expressing cells (Fig. 2.4C, 
solid line) but no response in hA2BR + Gqs-expressing cells (Fig. 2.4C, dashed line).  ACP, 
AMP and adenosine also evoked rapid calcium responses in COS7 cells expressing hA1R + 
Gqi, but not Gqi alone, indicating that all of these compounds activate hA1R when expressed 
in a different cell line (Fig. 2.5).
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Figure 2.4.  A non-hydrolyzable AMP analog activates hA1R but not hA2BR. 
 A and B)  Structures of (A) AMP and (B) the non-hydrolyzable analog ACP at 
physiological pH.  C)  Calcium mobilization responses elicited by 1 mM ACP in HEK293 
cells expressing (solid line) hA1R + Gqi or (dashed line) hA2BR + Gqs.  Cells expressing Gqi 
alone did not respond to ACP.  AUC measurements extended for 1 minute from agonist 
addition.  Paired t tests were used to compare AUC data.  ***, p < 0.0005.  Data are the 
average of one (hA2BR) or two (hA1R) experiments performed in duplicate.  n = 28-73 cells 
per condition.  All data, including calcium traces, are presented as means ± standard error.
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Figure 2.5.  Adenosine, AMP and ACP stimulate calcium mobilization in COS7 cells. 
 Calcium mobilization in COS7 cells expressing (black) hA1R + Gqi or (grey) Gqi 
alone, and stimulated with the indicated compounds (at 1 mM).  AUC measurements 
extended for 1 minute from agonist addition.  Paired t tests were used to compare AUC data 
in the presence and absence of transfected hA1R.  **, p < 0.005; ***, p < 0.0005.  All 
experiments performed in duplicate.  n = 15-21 cells per condition.  All data are presented as 
means ± standard error.
 34 
Adenosine and AMP are equipotent hA1R agonists 
 Since our experiments above were performed using a single concentration of agonist, 
we next performed dose-response experiments to determine agonist potency in hA1R + Gqi-
expressing cells (Fig. 2.6).  We found that adenosine stimulated calcium responses with an 
EC50 of 1.41 µM (Table 1), a value consistent with previously published measurements 
(71,89).  Interestingly, the EC50 and Emax of AMP in the absence or presence of αβ-met-ADP 
(to ensure AMP was not hydrolyzed by endogenous NT5E) were not significantly different 
from those of adenosine (Fig. 2.6, Table 1).  The non-hydrolyzable analog ACP had an EC50 
of 26.1 µM, 15 fold higher than AMP.  This reduced potency relative to AMP could reflect 
the charge difference between the phosphonate and phosphate groups (monoanionic verses 
dianionic at neutral pH, respectively, Fig. 2.4).  The adenosine deamination product inosine 
had an EC50 of 38.1 µM, 27 fold higher than adenosine.  The high potency A1R agonist 2-
chloro-N
6
-cyclopentyladenosine (CCPA) evoked calcium responses with an EC50 of 3.32 
nM.  The Hill slopes of all dose responses were near 1.   
 To test the potency of these compounds in an assay that does not depend on the use of 
chimeric G proteins, we utilized a modified Promega GloSensor assay (Fig. 2.7, see 
Materials and Methods for assay details).  This assay measures agonist effects on 
isoproterenol-evoked cAMP accumulation using a luminescent reporter construct, and is 
conducted in cells containing only endogenous G proteins.  When stimulating hA1R-
expressing cells with adenosine, we observed a bimodal dose response, with adenosine 
inhibiting cAMP accumulation at low concentrations and stimulating cAMP accumulation at 
high concentrations (Fig. 2.7B).  The latter response was likely due to activation of Gs-
coupled A2 receptors, which HEK293 cells endogenously express (62,87).  Indeed, adenosine 
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stimulated additional cAMP accumulation in cells transfected with empty vector (Fig. 2.8B).  
This bimodal response prevented us from obtaining an EC50 value for adenosine.   
 In contrast, CCPA, AMP, ACP, and inosine exclusively inhibited cAMP 
accumulation in hA1R-expressing cells (Fig. 2.7 A, C-F) but had no effects in cells 
transfected with empty vector (Fig. 2.8 A, C-E).  Incubation with 100 ng/ml pertussis toxin 
for 16 hr post-transfection abolished the A1R-mediated inhibition of cAMP accumulation by 
adenosine, AMP, and CCPA (data not shown), confirming that signaling was mediated 
through endogenous Gi proteins.  The rank order of agonist potency was similar between 
cAMP accumulation assays and calcium mobilization assays (Table 1).  The EC50 values of 
AMP were not significantly different in the presence or absence of 10 µM αβ-met-ADP (Fig. 
2.7 C,D), further indicating AMP stimulates hA1R/Gi-coupled signaling directly and 
independent of hydrolysis to adenosine.  Moreover, AMP did not produce a bimodal 
response like adenosine, arguing that the signaling effects of AMP were specific to hA1R and 
not due to hydrolysis to adenosine.
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Figure 2.6.  Dose-response curves for adenosine, AMP and related analogs at hA1R. 
 Calcium mobilization in HEK293 cells expressing hA1R + Gqi and stimulated with 
the indicated compounds.   For AMP + αβ-met-ADP condition, cells were incubated with 10 
µM αβ-met-ADP for 3 minutes and then were stimulated with AMP in the presence of 10 
µM αβ-met-ADP.  AUC measurements extended for 1 minute from agonist addition.  All 
experiments performed in duplicate.  n = 19-45 cells per condition.  All data are presented as 
means ± standard error.
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Figure 2.7.  Adenosine, AMP and related analogs inhibit cAMP accumulation in hA1R-
expressing cells. 
 HEK293T cells were co-transfected with a vector encoding hA1R and GloSensor 22F 
plasmid then stimulated with (A) CCPA, (B) adenosine, (C) AMP, (D) AMP in the presence 
of 10 µM αβ-met-ADP, (E) ACP, or (F) inosine.  Cells were incubated with test compound 
for 10 minutes, then 175 nM (-)-isoproterenol was added for 7 minutes to stimulate cAMP 
accumulation.  Following incubation, GloSensor cAMP reagent was added and luminescence 
was measured.  Data were normalized such that 100% inhibition is equal to the response at 
the maximal concentration of CCPA and 0% is equal to the response from isoproterenol 
alone.  All experiments were performed in duplicate.  All data are presented as means ± 
standard deviation.
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Figure 2.8.  Adenosine, AMP and related analogs do not inhibit cAMP accumulation in 
cells lacking hA1R. 
 HEK293T cells were co-transfected with empty expression vector and GloSensor 22F 
plasmid then were stimulated with (A) CCPA, (B) adenosine, (C) AMP, (D) ACP, and (E) 
inosine.  Cells were incubated with test compound for 10 minutes, then 175 nM (-)-
isoproterenol was added for 7 minutes to stimulate cAMP accumulation.  Following 
incubation, GloSensor cAMP reagent was added and luminescence was measured.  All data 
were normalized such that 0% is equal to the response from isoproterenol alone.  All 
experiments performed in duplicate.  All data are presented as means ± standard deviation.
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Table 1 
hA1R dose responses for Ca
2+
 mobilization assay and Glosensor assay 
   Inhibition of 
 Ca
2+
 mobilization cAMP accumulation 
Agonist EC50 (µM) Emax (%)* EC50 (µM) 
CCPA 0.00332 104.3 ± 2.0 0.0171 
Adenosine 1.41 100 -- 
AMP 1.69 94.1 ± 14.1 0.816 
AMP
#
 1.11 99.6 ± 3.3 0.601 
ACP 26.1 69.4 ± 3.2 4.95 
Inosine 38.1 97.2 ± 3.6 3.22 
* Relative to adenosine;  # In presence of 10 µM αβ-met-ADP 
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ACP inhibits forskolin-evoked cAMP accumulation in embryonic mouse cortical neurons 
 Since the experiments above relied upon overexpression of adenosine receptors, to 
further assess physiological relevance, we next sought to determine if the non-hydrolyzable 
AMP analog (ACP) could activate native A1R and native downstream signaling components 
in a primary cell type.  We selected mouse embryonic cortical neurons because AMP directly 
activates mA1R (Fig. 2.3), mA1R is highly expressed (Fig. 2.9A) and A1R activation 
regulates the physiology of cortical neurons (83).  We utilized a cAMP ELISA assay to 
measure the second messenger that is downstream of Gi-coupled mA1R.  In addition, we used 
ACP to ensure that no adenosine was produced from endogenously expressed 
ectonucleotidases. 
 Stimulation of cortical neurons with the adenylyl cyclase activator forskolin (10 µM) 
for 15 minutes increased intracellular cAMP concentration by 10-fold compared to baseline 
(Fig. 2.9B, blue).  The concentration of cAMP in neurons treated with 1 mM ACP for 30 
minutes prior to forskolin stimulation was decreased 34.9% compared to neurons treated with 
forskolin alone (Fig 2.9B, green), and cAMP concentration decreased 57.2% in neurons 
treated with 1 µM N
6
-cyclopentyladenosine (CPA; Fig 2.9B, purple), a high potency A1R 
agonist.  In addition, the potent A1R antagonist CPX (100 µM) completely blocked the 
effects of ACP and CPA, as evidenced by no decrease in cAMP concentration compared to 
forskolin alone (Fig 2.9C).  Thus, these data indicate that a nonhydrolyzable AMP analog can 
directly activate endogenous signaling pathways downstream of endogenously expressed 
A1R (i.e. in cells that were not subjected to any genetic manipulation).
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Figure 2.9.  ACP inhibits cAMP accumulation in mouse embryonic cortical neurons. 
 Embryonic cortical neurons were dissociated and plated at approximately embryonic 
day 16.5.  A)  Confocal image of cortical neurons immunostained with an anti-A1R antibody.  
Scale bar = 10 µm.  B and C)  After 1 day in vitro, neurons were incubated for 30 minutes 
with 1 mM ACP or 1 µM CPA in the (B) absence or (C) presence of 100 µM CPX.  Neurons 
were then stimulated with 10 µM forskolin for 15 minutes, washed, and lysed.  Cell lysates 
were then applied to a cAMP ELISA assay according to manufacturer’s instructions.  cAMP 
concentrations were normalized to total protein using a BCA protein assay.  Blue asterisks, 
statistically significant difference compared to forskolin stimulation alone.  *, p < 0.05; **, p 
< 0.005; ***, p < 0.0005.  Data are the average of four (- CPX) or two (+ CPX) experiments 
performed in duplicate.  All data are presented as means ± standard error.
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AMP stimulates hA1R independent of P2Y receptors 
 HEK293/T cells express multiple P2Y receptors (64,90) and P2Y receptors can 
heterodimerize with A1R, imparting a P2Y-like pharmacology on A1R (91-93).  In addition, 
P2Y receptors can be stimulated by AMP analogs but not by AMP (94).  Thus, we evaluated 
whether AMP-evoked calcium responses in hA1R-expressing cells could be blocked with 
non-selective P2Y antagonists (PPADS or suramin).  We found that stimulation of 
untransfected HEK293 cells with 10 µM ATP elicited a rapid calcium response (Fig. 2.10A, 
grey).  This response was blocked completely by 100 µM PPADS (Fig. 2.10A, blue) and by 
100 µM suramin (Fig. 2.10A, green).  However, the same concentrations of PPADS or 
suramin did not block calcium responses in hA1R + Gqi-expressing cells that were stimulated 
with 10 µM adenosine (Fig. 2.10B) or 10 µM AMP (Fig. 2.10C).  These data thus indicate 
that AMP signals directly through hA1R, independent of P2Y receptor activity. 
 
His251 and His278 in the ligand binding pocket are required for AMP to directly activate 
hA1R 
 The crystal structures of an adenosine receptor (hA2AR) co-crystallized with 
adenosine and an adenosine analog were recently reported (10,11).  From these structural 
views of the ligand binding pocket, we selected two positively charged histidine residues 
(H251 and H278; conserved in hA1R) as possibly important for interacting with the 
negatively charged phosphate of AMP.  We then mutagenized each of these histidine 
residues to a nonpolar residue (alanine), to generate hA1R-H251A and hA1R-H278A.  We 
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confirmed that each mutant receptor was expressed and membrane-localized to the same 
extent as wild-type hA1R (Fig. 2.11 A-C).   
 Next, we measured adenosine and AMP potency at the mutant receptors with our 
calcium mobilization assay (Fig. 2.11D).  We performed these experiments in the presence of 
10 µM αβ-met-ADP to prevent AMP from slowly being hydrolyzed to adenosine.  In cells 
expressing hA1R-H251A + Gqi, adenosine stimulated calcium mobilization with an EC50 of 
1.80 µM, essentially identical to what we observed when stimulating wild-type hA1R with 
adenosine (Table 1).  Likewise, mutation of H251 did not affect binding of a radiolabled 
agonist to bovine A1R (95).  In contrast, the potency of AMP in hA1R-H251A + Gqi-
expressing cells was drastically reduced, so much so that we could not obtain a complete 
dose response.  In cells expressing hA1R-H278A + Gqi, we observed a very weak response 
after stimulation with 1 mM adenosine, but no response at lower concentrations.  
Furthermore, stimulation with 1 mM AMP elicited no response.  This is also consistent with 
a previous report, which showed that mutation of H278 abolished agonist binding (95).  
Taken together, our results provide compelling evidence that adenosine and AMP activate 
hA1R directly, with activation requiring an agonist binding pocket residue (H278) that is 
conserved in all adenosine receptors.  Furthermore, the positively charged H251 residue is 
critical for activation of hA1R by a negatively charged nucleotide (AMP) but not by 
adenosine.  Importantly, these mutagenesis experiments conclusively rule out the possibility 
that adenosine and AMP stimulate calcium mobilization through any other receptor in 
HEK293 cells.
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Figure 2.10 
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Figure 2.10.  AMP activates hA1R independent of P2Y receptor activity. 
 A)  Calcium mobilization responses in untransfected HEK293 cells stimulated with 
10 µM ATP in the absence or presence of P2Y receptor antagonists (PPADS or suramin).  B 
and C)  Calcium mobilization responses in HEK293 cells expressing hA1R + Gqi following 
stimulation with (B) 10 µM adenosine or (C) 10 µM AMP, in the absence or presence of 100 
µM PPADS or 100 µM suramin.  Cells were incubated in 100 µM PPADS/suramin for 3 
minutes prior to experiments.  AUC measurements extended for 1 minute from agonist 
addition.  Paired t tests were used to compare AUC data relative to agonist alone.  ***, p < 
0.0005.  All data are the average of (A) one or (B, C) two experiments performed in 
duplicate.  n = 21-74 cells per condition.  All data, including calcium traces, are presented as 
means ± standard error.
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Figure 2.11 
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Figure 2.11.  Expression and activity of hA1R point mutants. 
 A – C)  Confocal images of HEK293 cells expressing (A) wild-type hA1R, (B) hA1R-
H251A or (C) hA1R- H278A and immunostained with anti-A1R antibodies.  Untransfected 
HEK293 cells in the same field of view were not immunostained, confirming antibody 
specificity.  Scale bar = 10 µm.  D)  Calcium mobilization in HEK293 cells co-expressing 
indicated hA1R mutant and Gqi then stimulated with increasing concentrations of the 
indicated compounds.   For all conditions, cells were incubated with 10 µM αβ-met-ADP for 
3 minutes and then were stimulated with agonist in the presence of 10 µM αβ-met-ADP.  
AUC measurements extended for 1 minute from agonist addition.  All experiments 
performed in duplicate, except H278A – AMP, which was performed in triplicate.  n = 17-49 
cells per condition.  All data are presented as means ± standard error.
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DISCUSSION 
 Prior to our study, it was unknown if a receptor for AMP existed.  An older study 
suggested AMP might act directly and indirectly on adenosine receptors (73); however, the 
investigators did not fully inhibit the multiple ectonucleotidases that are now known to 
hydrolyze AMP to adenosine (75,77,78).  In addition, AMP has never been evaluated as an 
agonist with cloned adenosine receptors, possibly because all previous assays of adenosine 
receptor activation required relatively long incubation periods with agonist, causing 
uncertainty as to whether AMP or its hydrolysis product (adenosine) was the active 
compound. 
 Using a novel cell-based assay that allowed for real-time visualization of adenosine 
receptor activation, we found that AMP directly activated hA1R, independent of hydrolysis.  
In support of this conclusion, we found that AMP activated hA1R in HEK293 cells as 
effectively as adenosine, even after inhibition of the main ectonucleotidase in HEK293 cells.  
Furthermore, a non-hydrolyzable analog of AMP also activated hA1R in heterologous cells 
and in primary neurons, demonstrating that activation was not due to hydrolysis to adenosine.  
Our data thus provide the first direct evidence that hA1R is a receptor for the naturally 
occurring nucleotide AMP, and argue for reclassification of A1R as an adenosine and 
nucleotide (AMP) receptor.   
 Inbe and colleagues previously reported that GPR80/GPR99 was a receptor for 
adenosine and AMP, although others could not reproduce this result (62-64).  As suggested 
by Abbracchio and colleagues, GPR80/GPR99 may have been misidentified as a purinergic 
receptor because HEK293 cells (the cells used in the GPR80/GPR99 study and our present 
study) endogenously express P2Y receptors in addition to A2AR and A2BR.  Alternatively, 
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heteromeric interactions between GPR80/GPR99 and endogenous purinergic receptors could 
hypothetically impart GPR80/GPR99 with a novel pharmacological profile.   
 Neither of these hypothetical possibilities explains why AMP activated hA1R in our 
assays.  The HEK293 cells we used do contain A2 receptors (as evidenced by stimulation of 
cAMP production in cells transfected only with GloSensor plasmid, Fig. 2.8B) and P2Y 
receptors (as evidenced by ATP-evoked, P2Y antagonist-sensitive calcium responses, Fig. 
2.10A).  However, our data with P2Y antagonists rule out the possibility that AMP signaled 
through P2Y receptors.  In addition, point mutations in hA1R shifted or eliminated responses 
to AMP, providing strong evidence that AMP signaled directly through hA1R and not 
through any other receptor in HEK293 cells.  AMP also directly stimulated hA1R when 
expressed in a different mammalian cell line (COS7 cells; Fig. 2.5). 
 Our findings were also not an artifact of using a chimeric G protein to couple hA1R to 
calcium mobilization.  Indeed, we found that AMP (±αβ-met-ADP) and ACP activated hA1R 
when coupled to endogenous Gi proteins using the GloSensor cAMP accumulation assay and 
that this effect could be blocked by Gi-specific disruption with pertussis toxin.  Our findings 
were not an artifact of overexpressing A1R, as ACP inhibited forskolin-induced cAMP 
accumulation in mouse cortical neurons that contain only native A1R and downstream 
signaling components.   
 There is a large amount of structure-activity data with 5’-substituted adenosine 
analogs, all of which indicate that A1R is tolerant of bulky and negatively charged groups at 
the 5’-position (96-98).  This includes 5’-ester, 5’-carbamoyl, 5’-halogen and 5’-sulfide 
derivatives of adenosine analogs, many of which are low nanomolar agonists of A1R (99-
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102).  Despite this extensive literature with unnatural analogs, it is surprising that the most 
biologically relevant substitution – a 5’-phosphate – has never, to our knowledge, been 
directly tested as an A1R agonist.   
 Our data also revealed that a different adenosine receptor – hA2BR – is not activated 
by AMP or the non-hydrolyzable analog ACP.  Instead, hA2BR was only activated indirectly, 
following hydrolysis to adenosine.  These results shed light on seemingly conflicting reports 
of AMP acting directly as well as indirectly on adenosine receptors in some tissues but only 
indirectly via conversion to adenosine in other tissues (65,71-73,103,104).  Our data indicate 
that it is important to determine which adenosine receptor is activated when AMP is used as 
the ligand.  If A2BR is activated, the signaling effects of AMP should be indirect and fully 
dependent on ectonucleotidases.  In contrast, if A1R is activated, the signaling effects of 
AMP could be direct and indirect, with the level of direct activation dependent on AMP 
stability and ectonucleotidase levels.    
 We found that a non-hydrolyzable phosphonate analog of AMP could activate hA1R.  
Interestingly, other ectonucleotidase-resistant phosphonate analogs of AMP reportedly 
activate P2X receptors and have cardioprotective activity in vivo (105,106).  While it was 
suggested that the cardioprotective effects of these AMP analogs were due to P2X activation, 
P2X involvement was never directly tested in vivo with antagonists or knockout mice.  Given 
that A1R agonists also have cardioprotective effects (61), it is equally possible that the 
cardioprotective effects of these phosphonate analogs, and possibly AMP itself, are A1R-
mediated and not P2X-mediated. 
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 Our findings also have implications for AMP-based prodrugs that were designed to be 
full agonists for A2AR only after hydrolysis by ectonucleotidases (107).  Given our results 
and the extensive structure-activity data with substitutions at the 5’-position, these AMP 
prodrugs may display a complex pharmacology with direct A1R activation combined with 
indirect, hydrolysis-dependent A2AR activation.  Clearly, it will be important to rigorously 
evaluate the extent to which these and other AMP-based prodrugs activate A1R independent 
of hydrolysis.  This will require pharmacologically or genetically eliminating all of the AMP 
hydrolytic enzymes in a given tissue – a potentially daunting task given that numerous 
ectonucleotidases are present in complex tissues and are difficult to experimentally eliminate 
completely (79). 
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CHAPTER 3:  FURTHER INVESTIGATION OF A1R SIGNALING 
 
INTRODUCTION 
 The results presented in Chapter 2 raise several significant questions regarding the 
function of adenosine receptors.  Firstly, what causes the difference in AMP sensitivity 
between the A1 and A2B receptors?  Agonist sensitivity of GPCRs is usually thought to be 
determined by the residues in the receptor’s agonist binding site; that is, the residues that 
directly interact with the agonist in the final, activated conformation.  However, as detailed in 
Chapter 2, these residues are essentially completely conserved between the human A1 and 
A2B receptors (and therefore cannot be responsible for the difference in AMP sensitivity).  
Thus, the molecular mechanism(s) that determine the AMP sensitivity of adenosine receptors 
remains unknown. 
 Secondly, what explains AMP’s lack of in vivo antinociceptive activity?  The initial 
experiments in Chapter 2 (Fig. 2.2) were originally undertaken in order to better understand 
the activity of the pain-relieving ectonucleotidases prostatic acid phosphatase (PAP) and 
NT5E.  These enzymes reduce pain sensitivity when administered intrathecally (70,76) – or 
peripherally in the case of PAP (108) – by generating adenosine in situ.  The substrate for 
both enzymes is AMP, which is present in the extracellular environment at much higher 
levels than adenosine (109).  Furthermore, the effects of both PAP and NT5E are mediated 
by the A1 adenosine receptor.  Taken together with the results from Chapter 2, this brings to 
light an apparent paradox: if AMP and adenosine are equipotent A1R agonists (Fig. 2.6), why 
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does conversion of one into the other have any A1R-mediated effect at all?  Nevertheless, 
direct intrathecal injection of adenosine generates transient antinociceptive effects but 
injection of AMP does not (Dutton and Zylka, unpublished data), indicating that there is 
indeed a difference between AMP and adenosine in vivo. 
 Lastly, there is great interest in the development of A1 adenosine receptor agonists as 
pharmaceuticals.  In recent years there have been numerous A1 agonists in clinical trials for 
conditions as diverse as cardiac arrhythmia, angina, diabetes, and neuropathic pain (98).  
However, none of these compounds are based on an AMP scaffold.  Furthermore, many 
promising A1 agonists have encountered difficulties in clinical trials due to severe 
cardiovascular side effects and loss of efficacy due to A1 receptor desensitization (98).  Thus, 
the therapeutic potential of AMP-derived A1R agonists (and whether they will be subject to 
these problems) is worthy of further investigation. 
 Here, we set out to answer the above questions regarding adenosine receptor activity, 
primarily by adapting the calcium mobilization assay used extensively in chapter 2.  We 
found that the difference in AMP sensitivity between the human A1 and A2B receptors is at 
least partially determined by the sequence of the second extracellular loop, which likely 
affects the ability of AMP to access the agonist binding pocket by influencing the electrical 
charge on the extracellular face of the receptor.  Additionally, we found that although AMP 
and adenosine are equally potent and equally efficacious hA1R agonists through the Gαi-
coupled pathway, they exhibit dramatically different efficacies at hA1R through the Gαq-
coupled pathway.  This difference, or differential activation of other downstream effectors, is 
likely responsible for the discrepancy between AMP- and adenosine-evoked effects in vivo.  
Finally, we found that several AMP analogues are also potent hA1R agonists, and that one of 
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these compounds does indeed have significant A1R-mediated antinociceptive activity in 
mice.  Furthermore, this compound lacks the characteristic cardiovascular side effects caused 
by many adenosine receptor agonists, indicating that there may be therapeutic applications 
for AMP-derived drugs in the treatment of pain. 
 59 
MATERIALS AND METHODS 
 
Molecular Biology 
 The human Gαq expression construct was a gift from Dr. Bryan Roth.  A1R/A2BR 
loop-replacement chimeras were generated by traditional PCR-based mutagenesis and were 
sequence verified.  All other expression constructs were described previously (110).  ACP, 
3a, and 3d were synthesized as described previously (110,111). 
 
Calcium Imaging 
 All calcium mobilization experiments and the data analysis thereof were performed as 
described previously (110). 
 
Telemetry 
 Data Sciences International ETA-F20 transmitters were implanted as follows:  A 2 
cm midline abdominal incision was made in anesthetized mice. The transmitter was placed 
intra-abdominally on top of the intestines, parallel with the long axis of the body and the two 
leads pointing caudally. A large (14 gauge) needle was used to pass through the abdominal 
muscles on either side of the incision. The leads were passed through the lumen of the 
needle, one on each side and the needle was withdrawn. The leads were placed (positive by 
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the xiphoid and negative on the right pectoral) and anchored in place. The abdomen was 
closed with absorbable sutures and the skin with non-absorbable sutures.  
 
Note:  Figures 3.3 and 3.4, and the methods and results sections referring to them, are 
adapted from Korboukh et al (111) and constitute my personal contributions to that study.
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RESULTS 
Adenosine receptor sensitivity to AMP is partially determined by extracellular loop 2 
 We first set out to determine why the hA1 receptor is sensitive to AMP but the hA2B 
receptor is not, despite the fact that the residues in their respective binding pockets are nearly 
identical (11).  Although the amino acid sequences of the transmembrane helices are highly 
conserved between hA1R and hA2BR, the sequences of the extracellular loops (ELs) diverge 
significantly (Fig. 3.1A).  In fact, the net charge of the solvent-exposed extracellular faces of 
hA1R and hA2BR is very different, due to the composition of these loops (Fig. 3.1B).  
Furthermore, we previously found that negative charge was important in the activation of 
hA1R by AMP (110).  We therefore hypothesized that the relative AMP sensitivities of the 
hA1 and hA2B receptors may be determined by their extracellular charge. 
 In order to test this hypothesis, we created A1/A2B chimeric receptors in which EL1, 
EL2, or ELs 1 and 2 from hA1R were replaced with the equivalent loops from hA2BR.  We 
focused on ELs 1 and 2 because a homology model based on the crystal structure of the 
human A2A receptor (11) predicts that these loops are located in much closer proximity to the 
agonist binding pocket than either EL3 or the N terminus (not shown).  Furthermore, the net 
charge in EL3 does not vary between hA1R and hA2BR (Fig. 3.1B), suggesting that 
mutagenesis of this loop is likely to have little effect.  We then co-transfected the A1/A2B 
chimeras together with Gqi into HEK293 cells and measured calcium mobilization after 
stimulation with multiple concentrations of AMP.  We performed these experiments in the 
presence of 10 µM αβ-met-ADP, to block the hydrolysis of AMP into adenosine. 
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 We found that AMP potency and efficacy were very similar between WT hA1R (Fig. 
3.1C, pink; EC50 = 1.11 µM, Emax = 27.0) and the EL1 chimera (Fig. 3.1C, orange; EC50 = 
1.25 µM, Emax = 22.8), suggesting that EL1 does not play a significant role in determining 
the AMP sensitivity of hA1R and hA2BR.  However, AMP potency and efficacy were both 
drastically reduced in the EL2 chimera (Fig. 3.1C, olive; EC50 = 65.3 µM, Emax = 10.8), 
indicating that EL2 is a regulator of AMP sensitivity.  The EL1,2 chimera (Fig. 3.1C, green; 
EC50 = 28.3 µM; Emax = 9.6) responded similarly to the EL2 chimera, again suggesting that 
EL1 is not involved in AMP sensitivity.  As expected, we did not observe a calcium response 
after stimulating cells expressing WT hA2BR with any concentration of AMP (Fig. 3.1C, 
blue).  The potency and efficacy of adenosine was similar at WT hA1R and each of the 
chimeras (data not shown), indicating that modification of EL2 does not affect general 
receptor function.  There are likely other determinants of adenosine receptor AMP 
sensitivity, as the loss of AMP sensitivity in the EL2 and EL1,2 chimeras was not complete.  
However, our data strongly suggest that the composition of EL2 is an important determinant 
of AMP sensitivity in hA1R and hA2BR, likely by influencing the electrostatic charge 
immediately outside the agonist binding pocket.
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Figure 3.1 
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Figure 3.1.  Adenosine receptor sensitivity to AMP is partially determined by 
extracellular loop 2. 
 A)  Amino acid sequence alignment of hA1R and hA2BR.  Yellow, transmembrane 
domain.  Red, negatively charged residue.  Green, positively charged residue.  *, identical 
residues in hA1R and hA2BR.  :, similar residues in hA1R and hA2BR.  Grey box, N-terminus.  
Blue box, extracellular loop 1.  Red box, extracellular loop 2.  Green box, extracellular loop 
3.  B)  Comparison of net charge in the extracellular regions of hA1R and hA2BR.  C)  
Calcium mobilization in HEK293 cells expressing the indicated A1/A2B chimeras + Gqi and 
stimulated with AMP.  WT hA1: EC50 = 1.11 µM; Emax = 27.0.  hA1-(EL1)2B: EC50 = 1.25 
µM; Emax = 22.8.  hA1-(EL2)2B: EC50 = 65.3 µM; Emax = 10.8.  hA1-(EL1,2)2B: EC50 = 28.3 
µM; Emax = 9.6.  For all conditions, cells were incubated with 10 µM αβ-met-ADP for 3 
minutes and then stimulated in the presence of 10 µM αβ-met-ADP.  AUC measurements 
extended for 1 minute from AMP addition.  n = 11-43 cells per condition.  All data are 
presented as mean ± standard error.
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AMP and adenosine differentially activate Gαq through the A1 adenosine receptor 
 Administration of prostatic acid phosphatase (PAP) causes A1R-mediated 
antinociceptive effects by hydrolyzing AMP to adenosine in situ (76).  Additionally, 
intrathecal injection of adenosine causes short-lived antinociceptive effects, whereas 
intrathecal injection of AMP does not (Dutton and Zylka, unpublished data).  These results 
appear to conflict with our evidence that adenosine and AMP are equipotent A1R agonists 
(Fig. 2.6).  However, although primarily coupled to Gαi, hA1R is a ‘promiscuous’ GPCR, 
meaning that it can couple to multiple G proteins, including Gαs, and Gαq (112).  In fact, an 
adenosine analog with a bulky substituent at the 5’ position (similar to 5’-AMP) causes 
selective activation of Gαi over Gαq by A1R (112).  Furthermore, PAP’s antinociceptive 
effects are mediated by the depletion of PIP2 (113), a pathway downstream of Gαq.  Thus, we 
hypothesized that differential activation of Gαq downstream of A1R may explain AMP’s lack 
of antinociceptive activity, despite its A1 agonist activity. 
 To examine hA1R activation of Gαq, we repeated our adenosine and AMP calcium 
mobilization experiments, replacing the chimeric G protein Gqi with wild-type human Gαq.  
We found that in cells expressing hA1R + Gαq, stimulation with 1 mM AMP (Fig. 3.2 A,B; 
blue) evoked a much smaller calcium response compared to stimulation with 1 mM 
adenosine (Fig. 3.2 A,B; red).  This is a striking difference from the assay employing Gqi, in 
which adenosine and AMP evoked identical responses (Fig. 2.2).  Since Gαq is ubiquitously 
expressed, and should be present in HEK293 cells without overexpression, we also 
performed the experiment without transfecting Gαq.  In cells expressing only hA1R, 
stimulation with 1mM adenosine (Fig. 3.2 A,B; green) evoked a very small calcium 
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response, and stimulation with 1 mM AMP (Fig. 3.2 A,B; orange) evoked no response at all, 
consistent with a much lower level of Gαq expression.  
 We then examined the relative potency and efficacy of adenosine and AMP through 
Gαq by repeating our dose-response experiments in the same fashion.  We found that in cells 
expressing hA1R + Gαq adenosine (Fig. 3.2C, red; EC50 = 8.97 µM, Emax = 18.0) had 
moderately reduced potency and efficacy compared to cells expressing hA1R + Gqi (compare 
Fig. 3.2C to Fig. 2.6), consistent with preferential coupling of hA1R to Gαi.  Moreover, the 
efficacy of AMP (Fig. 3.2C, blue; EC50 = 7.69 µM; Emax = 7.90) was far lower than that of 
adenosine in cells expressing hA1R + Gαq, although the potencies of adenosine and AMP 
were similar.  Again, this is a very different result from the assay employing Gqi, in which 
both the potencies and efficacies of adenosine and AMP were essentially identical (Fig. 2.6).  
We did not observe significant calcium mobilization in cells expressing hA1R + Gαq after 
stimulation with 1 mM ACP (Fig. 3.2C, black), consistent with ACP’s low efficacy 
compared with AMP.  Taken together, these data suggest that adenosine and AMP may still 
have different effects in vivo – despite being equally potent and equally efficacious A1R 
agonists through Gαi – via differential activation of other downstream signaling pathways, 
including Gαq.
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Figure 3.2 
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Figure 3.2.  Adenosine and AMP have similar potencies but very different efficacies 
when stimulating hA1R activation of Gαq. 
 Calcium mobilization in HEK293 cells expressing hA1R.  A)  Real-time calcium 
mobilization profiles in cells expressing hA1R + Gαq or hA1R alone and stimulated with 1 
mM adenosine or AMP.  n = 54-75 cells per condition.  B)  AUC quantification of calcium 
mobilization.  C)  Adenosine and AMP dose responses in cells expressing hA1R + Gαq.  
Adenosine: EC50 = 8.97 µM; Emax = 18.0.  AMP: EC50 = 7.69 µM; Emax = 7.90.  n = 14-53 
cells per condition.  AUC measurements extended for 1 minute from agonist addition.  ***, p 
< 0.0005.  All data are presented as mean ± standard error.
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AMP analogues are potent A1R agonists 
 In order to investigate whether compounds similar to AMP have A1R agonist activity 
and/or antinociceptive activity, we synthesized a series of AMP analogues containing an N
6
-
cyclopentyl group, which is known to confer A1R subtype selectivity (114).  Nearly all of 
these compounds were potent agonists of hA1R in a cAMP accumulation assay identical to 
the one presented in Figure 2.7 (111).  We then selected compounds 3a (Fig. 3.3A, a 
representative phosphate ester) and 3d (Fig. 3.3B, a representative phosphate) and tested 
them in the hA1R + Gqi calcium mobilization assay.  The Emax of 3a and 3d were normalized 
to the Emax of adenosine in this assay. Both 3a (Fig. 3.3C, pink) and 3d (Fig. 3.3C, orange) 
were potent agonists of hA1R with EC50 values of 0.52 μM and 0.021 μM, respectively.  
Furthermore, the Emax of 3a and 3d were similar to that of adenosine, indicating that 3a and 
3d are full agonists at hA1R.  Therefore, using two distinct and complementary assay 
platforms, we confirmed that compounds 3a and 3d directly activate A1R-mediated 
signaling.
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Figure 3.3 
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Figure 3.3.  Compounds 3a and 3d are full agonists of human A1R in a calcium 
mobilization assay. 
 A and B)  Chemical structures of (A) 3a and (B) 3d at physiological pH.  C)  Calcium 
mobilization in HEK293 cells expressing hA1R + Gqi and stimulated with the indicated 
compounds.  3a: EC50 = 0.52 μM; and 3d: EC50 = 0.021 μM.  Adenosine (EC50 = 1.41 μM) 
was used as a positive control.  AUC measurements extended for 1 minute from agonist 
addition.  n = 27-50 cells per condition.  All data are presented as mean ± standard error.
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An AMP analogue has antinociceptive activity and lacks cardiovascular side effects in mice 
 Further experiments with our series of AMP analogues revealed that compound 3a 
has potent A1R-mediated antinociceptive effects in mice when administered orally or by 
intrathecal injection (111).  However, clinical applications of the currently available A1R 
agonists are hampered by their cardiovascular side effects (98).  To determine if compound 
3a affected cardiovascular function, we monitored heart rate and body temperature in wild-
type and A1R
-/-
 mice following oral administration (CPA was administered as a positive 
control). At the highest dose tested, a 5000 nmol/kg (2.39 mg/kg) single dose by oral 
administration, compound 3a had no to negligible effects on heart rate and body temperature 
in wild-type and A1R
-/-
 mice (Fig. 3.4 A,C).  On the other hand, CPA elicited a statistically 
significant decrease in heart rate and body temperature which lasted for 4 to 6 hours in wild-
type mice (Fig. 3.4 B,D), but not in A1R
-/-
 mice.  CPA caused a modest increase in heart rate 
in A1R
-/-
 mice, possibly reflecting known off-target activation of stimulatory A2 receptors 
(100,115).  Collectively, our results indicate that our novel A1R agonist 3a has potent 
antinociceptive effects but minimal to no cardiovascular side effects when administered 
orally at a high 5000 nmol/kg dose.  In contrast, the same high dose of CPA has 
antinociceptive effects and significant cardiovascular side effects.  These data suggest that 3a 
has a large therapeutic window, and uniquely lacks cardiovascular side-effects that are 
associated with other A1R agonists like CPA.
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Figure 3.4 
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Figure 3.4.  Compound 3a does not have long-lasting effects on heart rate or body 
temperature while CPA causes a significant decrease in heart rate and body 
temperature in wild-type mice. 
 A and C)  Effects of 3a on (A) heart rate and (C) body temperature in wild-type (red) 
and A1R
-/-
 (black) mice.  B and D)  Effects of CPA on (B) heart rate and (D) body 
temperature in wild-type (red) and A1R
-/-
 (black) mice.  Compounds were orally administered 
at 5000 nmol/kg immediately before telemetry recording began.  n = 8 C57BL/6 male mice 
per group for A1R
-/-
 body temperature measurements, 6 male mice per group for all other 
conditions.
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DISCUSSION 
 We found that that the difference in AMP sensitivity between hA1R and hA2BR is 
partially determined by the composition of extracellular loop 2, as replacement of EL2 in 
hA1R with the EL2 from hA2BR caused a dramatic drop in both AMP potency and efficacy 
(Fig. 3.1C).  Differences in ligand binding interactions are unlikely to mediate this effect, as 
no hA1R-hA2BR divergent residues in EL2 interact with AMP while it is in the hA1R binding 
pocket (based on our hA1R homology model, derived from the crystal structure of hA2AR).  
Rather, this effect is likely due to electrostatic repulsion, as the EL2 of hA2BR is more 
negatively charged than that of hA1R (Fig. 3.1B), and AMP is a negatively charged ligand.  
Interestingly, replacement of EL1 instead of or in addition to EL2 had no effect on AMP 
potency or efficacy (Fig. 3.1C), despite the fact that EL1 and EL2 have the same net charge 
difference between hA1R and hA2BR (Fig. 3.1B).  This suggests that extracellular loop 
position is also critical in influencing AMP sensitivity.  In our hA1R homology model EL2 is 
located immediately outside of the agonist binding pocket (in fact, a conserved phenylalanine 
residue in EL2 forms a π-stacking interaction with the purine moiety of adenosine (11)), 
while the other extracellular portions of hA1R are located farther away. We therefore propose 
that the negatively charged EL2 of hA2BR acts as a ‘gatekeeper’, restricting the access of 
anionic ligands (such as AMP) to the binding pocket, but allowing neutral ligands (such as 
adenosine) to pass freely. 
 Notably, the composition of EL2 is not responsible for the entire difference in AMP 
sensitivity between hA1R and hA2BR, as the EL2 and EL1,2 chimeric receptors retain some 
level of activity in response to AMP stimulation (Fig. 3.1C).  The origin of this remaining 
AMP sensitivity is not known.  One possibility is that the remaining sensitivity is determined 
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by the composition of the N-terminus, which was not mutated in our study.  However, there 
is reason to believe that this is not the case.  As mentioned above, in our hA1R homology 
model, EL2 is located immediately outside the agonist binding pocket.  Among the 
remaining extracellular portions of hA1R, EL3 is located the closest to the binding pocket, 
EL1 is located at an intermediate distance, and the N-terminus is located at the greatest 
distance.  Since mutation of EL1 had no effect on AMP sensitivity, it is unlikely that 
mutation of the N-terminus, which has the same net charge difference as EL1 (Fig. 3.1B) but 
is located farther from the agonist binding pocket, would have any significant effect.  In a 
similar fashion, the composition of EL3 is likely not relevant, as although it is located 
relatively close to the agonist binding pocket, it is well-conserved and possesses an identical 
net charge in both hA1R and hA2BR (Fig. 3.1B). 
 The other possibility is that AMP sensitivity is also partly due to differences in G 
protein coupling between A1R and A2BR.  A1R primarily couples to Gαi, whereas A2BR 
primarily couples to Gαs, although coupling to additional Gα subunits has been described for 
both receptors (112,116-118).  The characteristic G protein-coupling interfaces of hA1R and 
hA2BR are determined by the sequences of the intracellular loops, which are divergent 
between the two receptors (Fig. 3.1A).  Furthermore, AMP binds to the hA1R binding pocket 
through an interaction with histidine 251, whereas adenosine does not (Fig. 2.11D).  This 
unique binding interaction implies that the A1 receptor adopts a distinct conformation upon 
the binding of each ligand.  It is therefore possible that binding of AMP in the hA1R binding 
pocket causes a conformational shift which is sufficient to cause full activation of Gαi, but 
that this same conformational shift in hA2BR causes no or limited activation of Gαs.  Further 
investigation of this potential mechanism is warranted, but would entail mutagenesis of the 
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hA1R intracellular loops.  This would by definition change the coupling properties of the 
receptor, and likely necessitate the development of new downstream assays to measure 
receptor activity. 
 The recently-discovered phenomenon by which a single agonist, binding to a single 
GPCR, preferentially activates some downstream signaling pathways over others is known as 
functional selectivity (35,119).  Although the concept was first recognized less than 10 years 
ago, the potential implications of functional selectivity on drug discovery has quickly led to a 
significant body of work on the subject.  As such, functionally selective ligands have now 
been identified for multiple GPCRs (120-125), including the A1 and A3 adenosine receptors 
(112,126).  However, the vast majority of such studies have focused on synthetic agonists, as 
opposed to biological signaling molecules. 
 Here, we have shown that the physiologically relevant nucleotide AMP is a 
functionally selective agonist at the human A1 receptor.  AMP is a full agonist (i.e. its 
maximal response is equivalent to that of adenosine) of Gαi-coupled signaling through hA1R 
(Fig. 2.6), but only a partial agonist (i.e. a saturating agonist concentration elicits a smaller 
response than a saturating concentration of adenosine) of Gαq-coupled signaling through the 
same receptor (Fig. 3.2).  This is not dependent on overexpression of Gαq, as we also 
observed greater adenosine-evoked responses using endogenously expressed G proteins (Fig. 
3.2 A,B; green).  In fact, at endogenous levels of Gαq expression, AMP may not stimulate 
Gαq-coupled signaling through hA1R at all (Fig. 3.2 A,B; orange). 
 This effect is not caused by a deficiency in AMP binding to hA1R, as AMP has 
comparable potency to adenosine, even via pathways for which it is only a partial agonist 
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(Fig. 3.2C).  Rather, this effect is caused by deficient signal transduction between the 
intracellular face of hA1R and its associated G protein.  As discussed above, AMP and 
adenosine binding to hA1R generates two unique receptor conformations, as AMP forms a 
unique interaction with at least one residue in the hA1R binding pocket (Fig 2.11D).  Our 
data indicate that the AMP-induced conformation strongly promotes activation of Gαi, but 
only weakly promotes activation of Gαq.  In support of this mechanism, another hA1R 
agonist with a bulky 5’ substituent – the binding of which is therefore likely to cause a 
similar receptor conformation to that caused by the binding of AMP – also causes 
preferential activation of Gαi (112). 
 It is important to note that while adenosine is assumed to be a universal full agonist at 
A1R, this may not necessarily be the case.  There are other pathways activated downstream of 
A1R through which adenosine and AMP have not been compared, including Gαs-coupled and 
β-arrestin mediated signaling.  It is possible that AMP is a more efficacious A1R agonist than 
adenosine through another downstream effector.  Indeed, the discovery of functional 
selectivity has largely made obsolete the simple concept of a ‘full agonist’, and our results 
underscore the necessity of measuring multiple pathways downstream of GPCR activation in 
order to obtain a more complete understanding of a given compound’s true agonist activity. 
 We found that compound 3a (Fig. 3.3A) has potent antinociceptive activity in mice 
when delivered by intrathecal injection (111), while AMP (Fig. 2.4A) does not.  Although the 
basis for this difference in activity is not known, the structures of the two compounds are 
very similar.  In fact, there are only three structural modifications between AMP and 3a that 
could be responsible: 3a is a dimethyl ester, rather than a charged phosphate, and it contains 
both a 2-chloro and an N
6
-cyclopentyl group attached to the adenine moiety.  It is unlikely 
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that the addition of the methyl groups – which eliminates both negative charges from the 5’-
phosphate group – is responsible for 3a’s activity, as elimination of even one negative charge 
from the 5’-phosphate (in the compound ACP, Fig. 2.4B), had a deleterious effect on efficacy 
at hA1R (Fig. 2.6).  Indeed, compound 3d (Fig. 3.3B), which lacks these methyl groups, also 
has antinociceptive activity in mice (Coleman and Zylka, unpublished data). 
  The other set of modifications made to AMP to yield compound 3a are the addition of 
2-chloro and N
6
-cyclopentyl groups.  These groups were derived from the compound CCPA, 
an exceptionally potent (Fig. 2.6) and highly selective A1R agonist (114).  As the pain-
relieving effects of adenosine agonists are A1R-mediated (98), these ‘CCPA-like’ groups 
were added to some of our AMP analogues in an attempt to enhance A1R activity (111).  This 
effort was successful, as the ‘CCPA-like’ compounds 3a and 3d both displayed higher 
potency at hA1R than adenosine in the calcium mobilization assay (Fig. 3.3C).  Of these two 
substituents, the 2-chloro group appears to be less important, as another AMP analogue 
similar to 3a but lacking the 2-chloro group also had antinociceptive activity via intrathecal 
injection (Coleman and Zylka, unpublished data).  Thus, it appears that the N
6
-cyclopentyl 
ring is the critical structural component conveying in vivo antinociceptive activity to the 
AMP scaffold. 
 Furthermore, we found that oral administration of compound 3a (Fig. 3.4 A,C) did 
not cause the cardiovascular side effects characteristic of A1R agonists (Fig. 3.4 B,D; CPA 
used as representative A1R agonist).  This difference in side effect profile was unexpected, as 
depression of heart rate and body temperature is A1R-mediated (Fig. 3.4 B,D; compare wild-
type C57BL/6, red, to A1R
-/-
, black), and 3a is a potent A1R agonist (Fig 3.3C) (111).  
Interestingly, intracerebroventricular injection of an A1R agonist was recently shown to 
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severely depress heart rate and body temperature in rats (127), suggesting that the 
cardiovascular effects of A1R agonists are at least partially mediated by the central nervous 
system (CNS).  Since 3a was administered orally in this experiment, this raises the possibility 
that 3a may lack cardiovascular side effects because it cannot cross the blood-brain barrier 
and access the CNS.  However, A1R agonists also have direct inhibitory effects on the heart 
itself.  Thus, the lack of cardiovascular effects may be caused by differential signaling 
downstream of A1R, as 3a has only been evaluated in Gαi-coupled assays of A1R activity. 
 The other problem that has plagued A1R agonists in the clinic – the rapid 
development of tolerance due to A1 receptor desensitization (98) – has not been evaluated 
using AMP-derived agonists.  GPCR desensitization is largely mediated by β-arrestin 
signaling (128), which is activated in a distinct fashion from G protein-mediated signaling 
(21).  Once again, this suggests that differential activation of multiple downstream signaling 
pathways may be critical in determining if AMP-derived A1R agonists realize their 
therapeutic potential.  The ideal A1R-mediated pain therapeutic will need to be CNS-
impermeable – to avoid cardiovascular side effects as much as possible, although specific 
activation of antinociceptive A1 receptors over those in the heart may prove to be an 
impossible task, at least with systemic drug administration – and functionally selective 
towards G protein signaling over β-arrestin signaling, to avoid the development of tolerance.  
Thus, whether focusing on 3a, other AMP analogues, or structurally unrelated A1R agonists, 
additional work is needed to determine if these compounds are CNS-penetrant and to fully 
characterize their A1R agonist activity. 
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CHAPTER 4:  OVEREXPRESSION OF DIACYLGLYCEROL KINASE ETA 
PROLONGS GPCR SIGNALING  
 
INTRODUCTION 
 Diacylglycerol kinases (DGKs) are a large family of enzymes that catalyze the 
phosphorylation of the membrane lipid diacylglycerol (DAG) to phosphatidic acid (PA) 
(129,130).  Both DAG and PA are important second messengers and regulate diverse 
proteins and pathways, including protein kinase C (PKC) (30,131), ion channels (132), 
endocannabinoid production (133), and phosphatidylinositide synthesis (134).  Thus, by 
affecting the levels of DAG and PA, DGKs are well positioned to regulate diverse 
intracellular signaling pathways (135). 
 In recent years, a number of studies have identified genetic associations between 
DGKH and bipolar disorder (BPD) (136-141).  DGKH is the gene that encodes 
diacylglycerol kinase eta (DGKη).  Moreover, Moya and colleagues found that DGKη 
mRNA was expressed at higher levels in post-mortem tissue samples from patients with BPD 
than unaffected controls (142).  DGKη is a Type II DGK isoform with two known splice 
variants (143-145), and was recently implicated in lung cancer (146).  However, how 
alterations in DGKη levels might affect cellular functions or contribute to BPD pathogenesis 
is currently unknown. 
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 Dysregulation of G protein-coupled receptor (GPCR) activity is involved in the 
pathology of many psychiatric disorders, including BPD (147).  Indeed, tissues from BPD 
patients exhibit changes in GPCR (148) and G protein subunit (149,150) expression, 
enhanced receptor-G protein coupling (151), and decreased expression of a GPCR-regulating 
kinase (150).  Furthermore, therapeutic concentrations of lithium and valproate, common 
treatments of BPD, inhibit G protein activation after GPCR stimulation in cell membranes 
(152) and platelets from bipolar patients (153). 
 Given that DGKη is expressed at higher levels in BPD patients and has the potential 
to affect GPCR signaling, we sought to determine if overexpression of DGKη affected GPCR 
signaling in HEK293 cells, a model cell line with well-characterized GPCR signaling 
cascades (154).  Here, we found that overexpression of DGKη dramatically prolonged the 
duration of calcium responses after stimulating endogenous Gαq-coupled GPCRs.  This 
DGKη-mediated effect was dependent on DGKη catalytic activity and was abolished after 
depleting multiple PKC isoforms.  Taken together, our data indicate that DGKη prolongs 
GPCR signaling by attenuating PKC activity and suggest this occurs by attenuating PKC-
dependent receptor desensitization.
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MATERIALS AND METHODS 
Materials 
 Carbamoylcholine chloride (carbachol, C4382), D-sorbitol (S1876), n-butanol 
(B7906), ethylenediaminetetraacetic acid (EDTA, EDS), phenylmethanesulfonyl fluoride 
(PMSF, P7626), sodium fluoride (201154), DL-dithiothreitol (DTT, D0632), sodium 
deoxycholate (D6750), adenosine 5’-triphosphate disodium salt (ATP, A7699), HEPES 
sodium salt (H7006), glycerol (G7893), sodium pyrophosphate (P8135), Dulbecco’s 
phosphate buffered saline (PBS, D8537), and fatty acid-free BSA (A6003) were purchased 
from Sigma-Aldrich.  Concentrated hydrochloric acid (A144SI), Tris hydrochloride (Tris-
HCl, BP153), sodium chloride (NaCl, BP358), magnesium chloride hexahydrate (MgCl2, 
BP214), Triton X-100 (BP151), Tween 20 (BP337), and D-glucose (D16) were purchased 
from Fisher Scientific.  Nonidet P40 substitute was acquired from USB Corporation (NP40, 
19628).  [γ-32P]-labeled ATP (6000 Ci/mmol, 150 mCi/ml) was obtained from Perkin Elmer 
(NEG035C005MC). 
 
Molecular Biology 
 A full-length clone of mouse DGKη isoform 1 was generated by PCR amplification 
using cDNA from C57BL/6 mouse neurons as a template (bases 1-3471 from GenBank 
accession #NM_001081336.1) (143).  The initial clone was found to be unstable due to high 
GC content at the 5’ end of the DGKη coding sequence.  To remedy this problem, the first 70 
bases of the DGKη coding sequence were modified to decrease GC content while preserving 
the wild-type (WT) DGKη amino acid sequence (native sequence: ATGGCCGGGG 
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CCGGCAGCCA GCACCACCCT CAGGGCGTCG CGGGAGGAGC GGTCGCTGGG 
GCCAGCGCGG; modified sequence: ATGGCAGGAG CAGGAAGTCA GCATCATCCT 
CAGGGAGTTG CAGGAGGAGC AGTTGCAGGA GCAACTGCAG).  The resulting 
construct was stable and was used to generate all subsequent constructs.  DGKη truncation 
constructs were generated by PCR amplification.  The G389D point mutant was generated by 
traditional PCR-based mutagenesis.  Full-length DGKη and all DGKη constructs were 
inserted into the multiple cloning site of pcDNA 3.1(+) downstream of monomeric RFP 
lacking a stop codon, to create fusion constructs with N-terminal RFP tags.  A DGKη-646Δ 
fusion construct with an N-terminal Venus tag was generated in the same fashion.  All 
constructs contained a Kozak consensus sequence and were sequence verified. 
 
Cell Culture 
 HEK293 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, 
11995) containing 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin 
at 37°C and 5% CO2.  Cells were plated on polylysine-coated glass-bottom dishes (MatTek, 
P35G-0-10-C) for calcium imaging, polylysine-coated glass coverslips (Brain Research 
Laboratories, 2222) for immunostaining, and polylysine-coated 6-well plates (Corning, 3516) 
for all other experiments.  Twenty-four hours after plating, cells were transfected with 
Lipofectamine/Plus (Invitrogen) in serum-free DMEM according to the manufacturer’s 
instructions.  Each plate/well was transfected with 500 ng of each DNA construct, and the 
total amount of DNA per transfection was normalized to 1 µg with empty vector.  After 4 
hours, the transfection medium was replaced with fresh growth medium.  To deplete PKC 
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isoforms, cells were treated overnight with 300 nM phorbol 12-myristate 13-acetate (PMA; 
Sigma, P8139) in growth medium (155).  All experiments except those measuring ERK 
phosphorylation were performed 24 hours after transfection.  For experiments measuring 
ERK phosphorylation, 24 hours after transfection, the growth medium was replaced with 
serum-free DMEM and cultured for an additional 24 hours. 
 
Calcium Imaging 
 Calcium imaging was performed as described previously (110).  Briefly, HEK293 
cells expressing various DGKη constructs and controls were washed twice in HBSS assay 
buffer (Invitrogen #14025, supplemented with 9 mM HEPES, 11 mM D-glucose, and 0.1% 
fatty acid-free BSA, pH 7.3) and loaded with 2 µM Fura-2 AM (Invitrogen, F-1221) in 
0.02% Pluronic F-127 (Invitrogen, P3000-MP) in assay buffer for 1 hour at room 
temperature.  Cells were then washed three times in assay buffer, incubated at room 
temperature for 30 minutes, and imaged on a Nikon Eclipse Ti microscope.  A Sutter DG-4 
light source and Andor Clara CCD camera were used to image calcium responses.  500-ms 
excitation at 340 nm and 250-ms excitation at 380 nm was used for all experiments.  Fura-2 
emission was measured at 510 nm. 
 Fresh assay buffer was added prior to each experiment.  After 40 seconds of baseline 
imaging, the assay buffer was aspirated and agonist solution was added.  All solutions were 
aspirated and pipetted manually.  For experiments involving overnight treatment with PMA, 
300 nM PMA was present in all loading and wash solutions.  Only cells that expressed 
visible RFP fluorescence, had low baseline Fura-2 ratios (< 0.6), and responded to agonist 
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stimulation (Fura-2 ratio > 0.8 at any time after agonist addition) were analyzed.  For 
experiments using cells transfected with RFP-DGKη-Δ645 and Venus-DGKη-646Δ, only 
cells expressing both visible RFP fluorescence and visible Venus fluorescence were 
analyzed.  Real-time response profiles and area under curve (AUC) values were generated as 
described previously (110).  To control for day-to-day variation in calcium responses, control 
cells expressing RFP alone were tested as part of each experiment.  AUC values were then 
normalized such that RFP alone was set at a value of 1. 
 
Confocal Microscopy 
 HEK293 cells expressing RFP-DGKη were washed twice in HBSS assay buffer and 
imaged using a Yokogawa CSU-10 spinning disc confocal scanner mounted on a Nikon 
TE2000 microscope.  An Argon/Krypton laser light source and a Hamamatsu Orca-ER 
camera were used to image RFP-tagged DGKη.  After approximately 1 minute of baseline 
imaging, assay buffer was replaced with buffer containing 10 µM carbachol or 500 mM 
sorbitol, and imaging continued for an additional 15 minutes.  Solutions were removed and 
added by manual pipetting. 
 
Immunostaining 
 HEK293 cells expressing RFP were incubated in PBS alone or 300 nM PMA in PBS 
for 10 minutes at 37°C then fixed in ice-cold 4% paraformaldehyde (Fisher, T353) for 15 
minutes.  After incubating in 0.5% Triton X-100 in PBS for 15 minutes, coverslips were 
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blocked for 30 minutes in blocking solution [0.1% Triton X-100 and 5% normal goat serum 
(Invitrogen, PCN5000) in PBS] then incubated with Rabbit anti-PKCδ primary antibody 
(Santa Cruz Biotechnology, sc-937) in blocking solution overnight at 4°C.  Cells were then 
washed with 10% goat serum in PBS for 30 minutes and incubated in Alexa Fluor 488-
conjugated Goat anti-Rabbit secondary antibody (Invitrogen, A11008) and DRAQ5 nuclear 
dye (Cell Signaling, 4084S) in blocking solution for 1 hour at room temperature.  Cells were 
washed three times (5 minutes/wash) with PBS between each step.  Coverslips were mounted 
onto microscope slides (Fisher, 12-550-143) with Fluoro-Gel (Electron Microscopy Sciences, 
17985-10) and stored at 4°C until imaging.  Slides were imaged the following day on a Zeiss 
LSM 510 microscope, with Multiline Argon and Helium-Neon laser light sources and a 63x 
objective.  
 
Phospho-ERK Western Blotting 
 HEK293 cells expressing RFP alone or RFP-DGKη were cultured overnight in 
serum-free growth medium, then incubated with agonist (or vehicle) in serum-free growth 
medium for 5 minutes at 37°C.  Cells were then quickly washed with ice-cold PBS, and 
phosphoprotein lysis buffer was added [20 mM HEPES pH 7.4, 150 mM NaCl, 10 mM 
EDTA, 3 mM sodium pyrophosphate, 1% Triton X-100, 1x Complete Mini protease inhibitor 
cocktail (Roche, 11 836 153 001), 1x Phosphatase Inhibitor Cocktail 2 (Sigma, P5726)].  
After buffer addition, cells were frozen at -80°C and left overnight.  The lysed cells were 
thawed on ice and collected, and the lysates were clarified by centrifugation at 10,000g for 
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15 minutes at 4°C.  Protein content of the clarified lysates was measured using a BCA assay 
kit (Thermo, 23227) according to the manufacturer’s instructions. 
 A portion (20 µg) of each lysate was heated at 94°C for 5 minutes with an appropriate 
amount of 4x Laemmli sample buffer, and separated by SDS-PAGE on a 4-15% gradient gel 
(Bio-Rad, 456-1083) at 100 V for 1 hour.  Proteins were transferred to a PVDF membrane 
(Bio-Rad, 162-0174) at 100 V for 70 minutes on ice, and blocked with 5% nonfat milk (Bio-
Rad, 170-6404) in TBST (100 mM Tris-HCl pH 7.5, 165 mM NaCl, 0.1% Tween 20) for 1 
hour at room temperature.  Blots were then incubated with Rabbit anti-phospho-ERK (Cell 
Signaling, 4370S) or anti-total-ERK (Cell Signaling, 4695S) primary antibodies in 5% BSA 
(Sigma, A3912) in TBST overnight at 4°C.  The following day, blots were washed three 
times (5 minutes/wash) with TBST and incubated with IRDye800-conjugated Donkey anti-
Rabbit secondary antibody (LI-COR, 926-32213) in 5% nonfat milk/TBST for 1.5 hours at 
room temperature.  Blots were then washed three times (5 minutes/wash) with TBST and 
imaged on a LI-COR Odyssey CLx infrared imaging system.  Phospho-ERK and total-ERK 
blots were imaged simultaneously under identical conditions.  Band intensity was quantified 
using ImageJ image analysis software (National Institutes of Health). 
 
Co-immunoprecipitation 
 HEK293 cells expressing tagged DGKη truncation constructs or fluorescent tags 
alone were washed twice with ice-cold PBS and scraped into glycerol-Co-IP buffer 
containing 50 mM HEPES pH 7.4, 250 mM NaCl, 2 mM EDTA, 10% (v/v) glycerol, 0.5% 
(v/v) NP40, 1x protease inhibitor cocktail, and 1x phosphatase inhibitor cocktail.  Cellular 
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debris was removed by centrifugation at 10,000g for 10 minutes at 4°C and input aliquots of 
the clarified lysate were set aside.  The remaining lysate was then incubated with Chicken 
anti-GFP primary antibody (Aves Labs, GFP-1020) or normal Chicken IgY control (Santa 
Cruz, sc-2718) for 3 hours at 4°C with gentle mixing.  Agarose beads coupled to Goat anti-
Chicken IgY (Aves, P-1010) were then added to each sample and incubated for 1 hour at 
4°C.  The beads were washed four times (5 minutes/wash) with ice-cold glycerol Co-IP 
buffer, and bound proteins were eluted from the beads by incubation with Laemmli sample 
buffer for 15 minutes at 37°C.  Input and IP fractions were then separated by SDS-PAGE, 
transferred to PVDF membrane, and blotted as described above, using Rabbit anti-RFP 
primary antibody (Invitrogen, R10367).  After imaging, blots were re-probed with Rabbit 
anti-GFP primary antibody (Invitrogen, A11122) to determine the specificity of the 
precipitation.  Samples containing RFP alone were heated for 5 minutes at 94°C before SDS-
PAGE; samples containing RFP-DGKη constructs were not heated, because we found that 
DGKη protein and DGKη truncation constructs were undetectable on western blots when 
heated at 94°C. 
 
In-vitro Kinase Assay 
 The DGK in vitro kinase assay was adapted from previous studies (156,157).  
HEK293 cells expressing RFP-tagged DGKη (WT or truncation constructs) or RFP alone 
were washed twice with ice cold PBS and scraped into lysis buffer (50 mM Tris-HCl pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1x protease inhibitor cocktail, 1x phosphatase 
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inhibitor cocktail).  Cells were disrupted by brief sonication on ice, and debris was collected 
by centrifugation at 10,000g for 10 minutes at 4°C.  Clarified lysates were kept on ice. 
 The final reaction mixture contained 50 mM Tris-HCl pH 7.4, 100 mM NaCl, 20 mM 
NaF, 10 mM MgCl2, 1 mM DTT, 1 mM EDTA, 1 mM sodium deoxycholate, 0.5 mM DAG 
(8:0, 12:0, or 18:1), 1 mM [γ-32P]ATP (50 µCi/rxn), and lysate; reaction volume was 50 µl.  
A calculated amount of 1,2-dioctanoyl-glycerol (8:0 DAG), 1,2-dilauroyl-glycerol (12:0 
DAG), or 1,2-dioleoyl-glycerol (18:1 DAG)  in chloroform (Avanti Polar Lipids; 800800C, 
800812C, and 800811C respectively) was deposited in a glass tube under a stream of dry 
nitrogen gas.  The DAG was then resuspended in an appropriate amount of 5x kinase buffer 
(250 mM Tris-HCl pH 7.4, 500 mM NaCl, 100 mM NaF, 50 mM MgCl2, 5 mM DTT, 5 mM 
EDTA) and 10 mM sodium deoxycholate by brief bath sonication.  15 µl of the DAG 
suspension was added to a tube containing 20 µl of water, followed by 5 µl of 10 mM [γ-
32
P]ATP.  The reaction was initiated by adding 10 µl of lysate, incubated for 3 minutes at 
30°C, and then stopped by adding 25 µl of 12 N HCl followed by 750 µl of water saturated 
with n-butanol.  Lipids were extracted from the reaction mixture by adding 500 µl of n-
butanol, mixing thoroughly, and separating by centrifugation at 1,000g for 5 minutes.  450 µl 
of the organic phase was washed with 500 µl of n-butanol-saturated water and separated by 
centrifugation, with care taken not to disturb the aqueous phase.  350 µl of this organic phase 
was then washed again in the same fashion.  Finally, 250 µl of the washed organic phase was 
transferred to a scintillation vial containing 2 ml of ScintiSafe Econo 2 (Fisher, SX21-5) 
scintillation fluid, mixed gently, and counted on a LKB Wallac Rackbeta 1209 liquid 
scintillation counter. 
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 For experiments comparing different DGKη truncation constructs, 15 µl of each 
lysate sample used in the in-vitro kinase assay was analyzed by western blotting with Rabbit 
anti-RFP antibody as described above, and the band intensity was quantified.  The DGKη 
activity data were corrected for differences in expression, and normalized such that RFP 
alone was set at a value of 0, and wild-type DGKη was set at a value of 1. 
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RESULTS 
Mouse DGKη phosphorylates multiple DAG substrates 
 First, we set out to evaluate whether mouse DGKη isoform 1 was catalytically active 
(Fig. 4.1A shows domain structure of isoform 1).  To accomplish this, we transfected 
HEK293 cells with RFP-tagged DGKη or RFP only (control) expression constructs.  One day 
later, we prepared cell lysates, incubated these lysates with purified DAG substrates and [γ-
32
P]ATP, then monitored 
32
P-labeled phosphatadic acid (PA) formation (Fig. 4.1B).  This in 
vitro assay was previously used to monitor DGK activity (156,157).  We found that kinase 
reactions containing RFP-DGKη produced significantly more 32P-PA than reactions 
containing RFP alone (Fig. 4.1C) when 500 µM dioctanoyl (8:0), dilauroyl (12:0), or 
dioleoyl (18:1) glycerol was used as substrate.  Given that mouse DGKη could phosphorylate 
multiple DAG substrates, and that 18:1 DAG was previously used to characterize human 
DGKη and other DGK isoforms (143), we elected to use 18:1 DAG for subsequent 
experiments.  The Km of DGKη for 18:1 DAG was 18.4 µM (Fig. 4.1D), justifying our use of 
a saturating 500 µM DAG concentration for subsequent in vitro kinase reactions. 
 
DGKη prolongs intracellular calcium mobilization after GPCR stimulation 
 Since DGKη is expressed at higher levels in patients with bipolar disorder (142), we 
next sought to determine if overexpression of DGKη affects endogenous GPCR signaling.  
We focused our research on HEK293 cells because they endogenously express the M3 
muscarinic acetylcholine receptor, a Gαq-coupled GPCR that mobilizes intracellular calcium 
following stimulation with carbachol (154).  Moreover, M3 receptor desensitization and 
 93 
downstream signaling pathways have been extensively studied (154,158-162).  After 
stimulating with 10 µM carbachol, we found that the calcium mobilization response was 
dramatically prolonged in HEK293 cells expressing RFP-DGKη compared to RFP alone 
(Fig. 4.1E).  Based on quantifying the area under the curve (AUC), the carbachol-evoked 
calcium response in RFP-DGKη-expressing cells was 80% greater than in cells expressing 
RFP alone (p < 0.0005).  The N-terminal RFP tag did not affect DGKη activity, as untagged 
DGKη, HA-DGKη, and DGKη-mCherry also prolonged carbachol-evoked calcium 
responses (data not shown; we identified cells with untagged or HA-tagged DGKη by co-
transfecting with Venus, a yellow fluorescent protein). 
 We next investigated whether DGKη could prolong calcium mobilization 
downstream of other Gαq-coupled GPCRs.  To accomplish this, we stimulated HEK293 cells 
with 10 µM ATP, which elicits intracellular calcium mobilization by activating endogenous 
P2Y receptors (110).  We found that HEK293 cells expressing RFP-DGKη exhibited 
dramatically prolonged ATP-evoked calcium responses compared to cells expressing RFP 
alone (Fig. 4.1F).  When quantified by AUC, ATP-evoked calcium responses in RFP-DGKη-
expressing cells were 81% greater than responses in cells expressing RFP alone (p < 0.005).  
These data indicate that overexpression of DGKη can enhance calcium responses 
downstream of two different GPCRs.  Since calcium mobilization was more pronounced 
(longer duration) following endogenous M3 receptor activation, we focused the remainder of 
our experiments on DGKη modulation of M3 receptor activation.
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Figure 4.1 
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Figure 4.1.  Mouse DGKη is catalytically active and prolongs GPCR signaling. 
 A)  Domain architecture of DGKη.  PH = Pleckstrin Homology.  C1 = PKC 
homology domain 1.  aa = amino acid.  B)  Schematic of the reaction forming 
32
P-labeled PA 
from DAG and radiolabeled ATP.  C)  Full-length mouse RFP-DGKη is catalytically active.  
Lysates from HEK293 cells expressing (black) RFP alone or (red) RFP-DGKη were 
incubated with the indicated DAG substrates, each at 500 µM.  D)  
32
P-PA production from 
reactions containing the indicated concentrations of 18:1 DAG, catalyzed by lysates from 
HEK293 cells expressing RFP-DGKη.  Data were normalized to the signal in the absence of 
DAG substrate and fit to a Michaelis-Menton curve.  E and F)  Calcium mobilization in 
HEK293 cells expressing (black) RFP alone or (red) RFP-DGKη after stimulation with (E) 
10 µM carbachol or (F) 10 µM ATP.  AUC measurements extended for 4 minutes from 
agonist addition.  Data in C and D are the average of two experiments performed in 
duplicate.  Data in E and F are the average of three independent experiments; n = 41-104 
cells per condition.  Paired t tests were used to compare data.  **, p < 0.005; ***, p < 0.0005.  
All data, including calcium traces, are presented as means ± standard error.
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DGKη catalytic activity is required to prolong carbachol-evoked calcium mobilization 
DGKη, like all type II DGK isoforms, possesses a split catalytic domain (130).  To 
determine if DGKη catalytic activity was required to prolong carbachol-evoked calcium 
mobilization, we generated two DGKη deletion constructs, DGKη-Δ645 and DGKη-646Δ, 
each containing one half of the catalytic domain (Fig. 4.2A).  We also generated DGKη-
G389D, containing a point mutation that is predicted to abolish ATP binding based on 
homology to other DGK proteins (163).  We found that DGKη-Δ645, DGKη-646Δ and 
DGKη-G389D were expressed (Fig. 4.3, Fig. 4.2E) but were catalytically inactive, as they 
generated no more 
32
P-PA than lysates containing RFP alone (Fig. 4.2B).  In contrast, lysates 
from cells co-expressing DGKη-Δ645 and DGKη-646Δ displayed specific activity 
approximately 32% of that of wild-type (WT) RFP-DGKη (Fig. 4.2B), suggesting the two 
halves directly interact.  Indeed, we found that RFP-DGKη-Δ645 co-immunoprecipitated 
with Venus-DGKη-646Δ (Fig. 4.2C).  This interaction was specific to DGKη-Δ645 and 
DGKη-646Δ and did not involve the fluorescent tags or non-specific binding to the 
immunoprecipitation beads, as evidenced by controls showing no interaction when either 
construct was replaced with a fluorescent protein alone or when the anti-GFP antibody was 
replaced with an IgY control (Fig. 4.2C). 
 Additionally, none of these catalytically dead constructs (DGKη-Δ645, DGKη-646Δ 
or DGKη-G389D) prolonged calcium mobilization after carbachol stimulation (Fig. 4.2D).  
Cells expressing DGKη-646Δ alone appeared unhealthy and displayed a slight reduction in 
calcium mobilization.  In contrast, co-expression of each half of DGKη (RFP-tagged DGKη-
Δ645 and Venus-tagged DGKη-646Δ) increased calcium mobilization by 62% (based on 
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AUC measurement, Fig. 4.2D).  Our data clearly indicate that DGKη catalytic activity is 
required to prolong carbachol-evoked calcium mobilization.   
 We also tested the catalytic activity of several DGKη truncation mutants lacking 
structural domains (Fig. 4.4A).  We found that the PH domain and C-terminal tail negatively 
regulated DGKη catalytic activity and that the C1 domains were required for catalytic 
activity (Fig. 4.4 B,D).  Furthermore, catalytic activity closely correlated with the ability to 
prolong carbachol-evoked calcium mobilization (Fig. 4.4C).  
 We next analyzed calcium mobilization AUC data on a cell-by-cell basis, to 
determine if the expression level of DGKη correlated with how effectively DGKη prolonged 
calcium mobilization responses.  Notably, there was no relationship between the level of 
DGKη expression and the extent of calcium mobilization in cells expressing WT DGKη or 
kinase-dead DGKη-G389D (Fig. 4.2E).  There was also no significant difference in the 
expression level of WT DGKη and DGKη-G389D across individual cells.  Similarly, no 
correlation between DGKη expression and calcium mobilization was observed for any of the 
DGKη truncation constructs (Figs. 4.3 & 4.4; data not shown).  Taken together, these data 
suggest that the amount of DGKη required to maximally prolong carbachol-evoked calcium 
mobilization is very small, perhaps because only a small amount of DAG substrate is 
generated upon M3 receptor activation.  In support of this possibility, we did not detect an 
increase in DAG levels after activating the endogenous M3 receptor with carbachol (with a 
sensitive DAG biosensor—Upward DAG2, data not shown) (164).
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Figure 4.2.  DGKη catalytic activity is required to prolong GPCR signaling. 
 A)  Structure of the DGKη truncation constructs used.  DGKη-G389D contains a 
point mutation in catalytic domain A (not shown).  All DGKη constructs were N-terminally 
tagged with RFP unless otherwise noted.  B)  Production of 
32
P-PA in reactions containing 
lysates from HEK293 cells expressing the indicated DGKη constructs, using 500 µM 18:1 
DAG as substrate.  Data were normalized to DGKη expression, which was assessed by 
western blotting against RFP, then normalized so that RFP alone = 0 and WT DGKη = 1.  
Data are the average of two experiments performed in duplicate.  C)  N- and C-terminal 
halves of DGKη interact.  Lysates from HEK293 cells expressing RFP-tagged DGKη-Δ645 
and Venus-tagged DGKη-646Δ or fluorescent protein controls were immunoprecipitated 
using an anti-GFP antibody or an IgY control.  Input and precipitated fractions were then run 
on SDS-PAGE and blotted using an anti-RFP antibody.  The blot was later re-probed with an 
anti-GFP antibody to verify the specificity of the immunoprecipitation.  D)  AUC 
measurements of calcium mobilization in HEK293 cells expressing the indicated DGKη 
constructs after stimulation with 10 µM carbachol, normalized such that RFP alone = 1.  
AUC data for the RFP and WT DGKη conditions is also presented, in non-normalized form, 
in Fig. 4.1E.  Data are the average of three to six independent experiments.  n = 58-162 cells 
per condition, except DGKη-646Δ, where n = 23.  E)  Scatter plot comparing calcium 
mobilization AUC measurements to DGKη expression levels in individual HEK293 cells 
expressing (red) WT DGKη or (gray) DGKη-G389D.  Horizontal dashed line indicates 
average level of calcium mobilization in HEK293 cells expressing RFP alone.  Vertical 
dashed line indicates average expression level of WT DGKη.  Paired t tests were used to 
compare data.  Black asterisks indicate a statistically significant difference when compared 
 100 
with RFP alone.  Red asterisks indicate a statistically significant difference when compared 
to WT DGKη.  *, p < 0.05; **, p < 0.005; ***, p < 0.0005.  All data are presented as means ± 
standard error.
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Figure 4.3.  Expression of DGKη truncation constructs in HEK293 cells. 
 HEK293 cells expressing the indicated DGKη constructs were lysed and western 
blotted using an anti-RFP antibody.  All DGKη constructs were N-terminally tagged with 
RFP.
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Figure 4.4.  Catalytic activity and signaling effects of DGKη truncation constructs. 
 A)  Domain architecture of the indicated DGKη constructs.  All constructs are N-
terminally tagged with RFP.  Δ645, 646Δ, and G389D constructs are discussed in Figure 4.2.  
B)  Production of 
32
P-PA in reactions with the indicated DGKη constructs, using 500 µM 
18:1 DAG as substrate.  Data were normalized to DGKη expression, which was assessed by 
western blotting against RFP, then normalized so that RFP alone = 0 and WT DGKη = 1.  
Data are the average of two experiments performed in duplicate.  In the enzymatic assay, the 
PH domain and the C-terminal tail of DGKη appear to have negative regulatory activity, as 
truncation of either domain led to increased specific activity.  The construct lacking both 
domains, 161Δ961, has a specific activity 6-fold higher than WT DGKη.  Both constructs 
lacking C1 domains were inactive.  As observed previously, the long splice isoform DGKη2 
had decreased catalytic activity relative to DGKη1 (143).  C)  AUC measurements of calcium 
mobilization in HEK293 cells expressing the indicated DGKη constructs after stimulation 
with 10 µM carbachol, normalized such that RFP alone = 1.  Data were not normalized to 
expression, as there was no relationship between expression and signaling effect for any of 
the DGKη constructs (data not shown, and see Fig. 4.2E).  Data are the average of three to 
six independent experiments.  n = 75-209 cells per condition.  In the signaling assay, 
truncation of the PH domain also resulted in a small increase in activity.  However, 
truncation of the C-terminal tail had no effect on activity in DGKη constructs with C1 
domains.  The 317Δ construct lacking C1 domains was inactive, but truncating the C-
terminal tail from this construct restored some degree of signaling activity.  DGKη2 had a 
very low level of activity, statistically indistinguishable from RFP alone (p = 0.057).  D)  
Speculative model of DGKη regulatory domain function; based on data from in vitro 
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enzymatic assays.  CT = C terminal tail.  Truncation of the PH domain or the C-terminal tail 
increases specific activity, suggesting that these domains inhibit the catalytic activity of 
DGKη, perhaps by restricting access of DAG and/or ATP to the DGKη active site (although 
not completely, as WT DGKη retains activity).  Inhibition by the PH domain and C terminal 
tail appear to be independent, as truncation of both domains increases catalytic activity in an 
additive manner.  The C1 domains are required for activity in this assay, as loss of the C1 
domains results in a complete loss of catalytic activity.  The SAM domain (not shown in 
Panel D, present only in DGKη2) also negatively regulates DGKη activity, possibly by 
enhancing inhibition by the C terminal tail.  Paired t tests were used to compare data.  Black 
asterisks, statistically significant difference when compared with RFP alone.  Red asterisks, 
statistically significant difference when compared to WT DGKη.  *, p < 0.05; **, p < 0.005; 
***, p < 0.0005.  All data are presented as means ± standard error.
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DGKη does not affect ER calcium loading or store-operated calcium entry 
 Next, to determine if DGKη prolonged calcium responses by affecting intracellular 
calcium stores, we treated RFP-DGKη-expressing cells and RFP-expressing controls with 
thapsagargin, a non-competitive sarco/endoplasmic reticulum calcium ATPase (SERCA) 
inhibitor that causes release of intracellular calcium stores into the cytosol (165,166).  
Calcium release was not significantly different between cells expressing RFP alone and RFP-
DGKη (Fig. 4.5A), indicating that DGKη has no effect on the loading of intracellular 
calcium stores. 
 When intracellular calcium stores become depleted, calcium-sensing proteins trigger 
the opening of calcium channels in the plasma membrane, allowing the entry of extracellular 
calcium, a process known as store-operated calcium entry (167,168).  To determine if DGKη 
prolonged calcium mobilization by affecting this process, we stimulated cells with carbachol 
in the absence of extracellular calcium (to abolish calcium entry through store-operated 
channels).  In the absence of extracellular calcium, carbachol-evoked calcium mobilization 
was reduced, particularly in the later stages of the response (compare Fig. 4.5B to Fig. 4.1E).  
However, overexpression of DGKη still prolonged the calcium response by 77% (based on 
AUC measurements) when compared to RFP alone.  This effect was nearly identical to the 
80% AUC increase in the presence of extracellular calcium.  Thus, these data indicate that 
DGKη prolongs the carbachol-evoked calcium response via a mechanism that is independent 
of store-operated calcium entry.
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Figure 4.5.  DGKη does not affect intracellular calcium stores. 
 Calcium mobilization in HEK293 cells expressing (black) RFP alone or (red) RFP-
DGKη after (A) stimulation with 1 µM thapsigargin or (B) stimulation with 10 µM carbachol 
in the absence of extracellular calcium.  AUC measurements extended 8 minutes (A) or 4 
minutes (B) after stimulation.  Paired t tests were used to compare AUC data.  ***, p < 
0.0005.  Data are the average of two (A) or five (B) independent experiments.  n = 69-190 
cells per condition.  All data, including calcium traces, are presented as means ± standard 
error.
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DGKη does not translocate after GPCR stimulation 
 Human DGKη localizes to the cytosol under baseline conditions and translocates to 
endosomes after osmotic shock (143,169).  However, whether DGKη translocates to the 
plasma membrane, where DAG is located, following GPCR stimulation is unknown.  Using 
live cell confocal imaging, we found that mouse DGKη is localized throughout the cytoplasm 
in unstimulated cells and did not translocate to the plasma membrane or any other subcellular 
compartment after stimulation with 10 µM carbachol (Fig. 4.6A).  This experiment was 
conducted under conditions that were identical to those used in the carbachol-evoked calcium 
mobilization assay, suggesting that the prolonged effects of DGKη on GPCR signaling 
require little if any translocation of DGKη to the plasma membrane.  Furthermore, we were 
unable to detect translocation of DGKη when cells were stimulated with 10 µM or 100 µM 
carbachol at 37°C (data not shown).  Our inability to detect DGKη translocation was not a 
technical limitation, as our mouse DGKη construct rapidly translocated to endosomes after 
osmotic shock (Fig. 4.6B), as previously shown using human DGKη (143,169). 
 
 DGKη prolongs GPCR signaling via attenuating PKC activation 
 DAG is a canonical activator of conventional and novel isoforms of PKC (30).  
Additionally, PKC is directly and indirectly involved in the phosphorylation and subsequent 
desensitization of GPCRs (44,170,171).  Therefore, we hypothesized that DGKη could 
prolong GPCR signaling by metabolizing DAG and hence reducing PKC activation.  To test 
this hypothesis, we used the phorbol ester PMA, which potently activates PKC (172).  First, 
we confirmed that acute treatment with 300 nM PMA could activate PKCδ in HEK293 cells, 
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as evidenced by rapid (within 2 minutes) translocation of PKCδ to the plasma membrane 
(Fig. 4.7A).  We then measured calcium mobilization after stimulating RFP- and RFP-
DGKη-expressing cells with 300 nM PMA followed immediately by 10 µM carbachol.  
Stimulation with 300 nM PMA profoundly accelerated the return of carbachol-evoked 
calcium mobilization to baseline (Fig. 4.7B, compare to Fig. 4.1E).  Furthermore, the 
carbachol-evoked calcium responses were identical in cells expressing RFP alone and RFP-
DGKη when PKC was acutely activated with 300 nM PMA (Fig. 4.7B).  In contrast, 
stimulation of RFP-expressing cells with 300 nM PMA alone did not evoke a calcium 
response (Fig. 4.7B).  Taken together, these data indicate that PKC activation blunts GPCR 
signaling in HEK293 cells and occludes the effect of DGKη. 
 We next took advantage of the fact that overnight stimulation with PMA is reported 
to lead to the near complete depletion of all PKC isoforms that are expressed in HEK293 
cells (155) except one (PKCδ was not tested in this reference).  We examined PKCδ and 
found that it was also significantly depleted by overnight stimulation with 300 nM PMA 
(Fig. 4.7C).  Furthermore, after culturing HEK293 cells overnight in 300 nM PMA, 
stimulation with 10 µM carbachol elicited identical calcium responses in cells expressing 
RFP alone and RFP-DGKη (Fig. 4.7D).  This was not due to a lack of DGKη, as there was 
no decrease in RFP-DGKη expression in cells cultured in 300 nM PMA compared to cells 
cultured in DMEM alone (data not shown).  Instead, these data indicate that DGKη 
potentiates GPCR signaling via PKC, likely by reducing the levels of a PKC activator (DAG) 
and attenuating PKC activity.
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Figure 4.6.  DGKη does not translocate within cells after GPCR stimulation. 
 Confocal images of live HEK293 cells expressing RFP-DGKη after stimulation with 
(A) 10 µM carbachol or (B) 500 mM sorbitol for the indicated times.  Cell culture and 
imaging conditions were identical to those used in calcium mobilization experiments.  Panel 
(A) shows cells from independent experiments.
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Figure 4.7.  DGKη prolongs GPCR signaling via PKC. 
 A)  PKCδ translocation following PMA stimulation.  Confocal images of HEK293 
cells after treatment with (left) vehicle or (right) 300 nM PMA for 2 minutes.  Cells were 
fixed, immunostained with an anti-PKCδ antibody (green), and counterstained with DRAQ5 
nuclear dye (blue).  B)  Calcium mobilization in HEK293 cells expressing RFP alone or 
RFP-DGKη after stimulation with (black, red) 300 nM PMA followed by 10 µM carbachol, 
or (blue) 300 nM PMA alone.  AUC measurements extended 80 seconds from final agonist 
addition.  Data are the average of two (PMA alone) or three (PMA + carbachol) independent 
experiments.  n = 49-83 cells per condition.  C)  HEK293 cells were cultured overnight in 
growth medium ± 300 nM PMA to deplete PKC isoforms.  Cells were lysed and 20 µg of 
protein from each lysate was run on SDS-PAGE and blotted using anti-PKCδ and anti-β-
actin antibodies.  (Right) Band intensities were quantified using ImageJ.  Data are the 
average of three independent experiments.  Overnight PMA treatment was previously shown 
to deplete all other PKC isoforms in HEK293 cells (155).  D)  Calcium mobilization in 
HEK293 cells expressing (black) RFP alone or (red) RFP-DGKη, after overnight culture in 
media containing 300 nM PMA.  Cells were stimulated with 10 µM carbachol.  AUC 
measurements extended 4 minutes from agonist addition.  Data are the average of four (RFP-
DGKη) or five (RFP alone) independent experiments.  n = 28-35 cells per condition.  Paired t 
tests were used to compare all data.  ***, p < 0.0005.  All data, including calcium traces, are 
presented as means ± standard error.
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DGKη reduces baseline and GPCR agonist-evoked ERK phosphorylation 
 Carbachol-evoked phosphorylation of ERK is mediated by PKCδ in HEK293 cells 
(154).  Thus, we next evaluated the extent to which overexpression of DGKη affected ERK 
phosphorylation.  We treated HEK293 cells expressing RFP or RFP-DGKη with vehicle, 10 
µM carbachol, or 300 nM PMA for 5 minutes, lysed the cells, and then ran western blots 
using a phospho-specific anti-ERK primary antibody (Fig. 4.8A).  After treatment with 
vehicle or 10 µM carbachol, RFP-DGKη cell lysates contained less phospho-ERK than 
lysates from RFP alone cell lysates (Fig. 4.8B).  The DGKη-evoked decrease in ERK 
phosphorylation was modest (approximately 20%), but statistically significant (p < 0.05), 
both at baseline and after carbachol stimulation.  This likely reflects the fact that not every 
cell was transfected with RFP-DGKη.  In contrast, after direct stimulation of PKC with 300 
nM PMA, which bypasses the need for DAG to activate PKC, there was no difference in 
ERK phosphorylation between lysates from cells expressing RFP alone and RFP-DGKη (Fig. 
4.8B).  Taken together, these data indicate that overexpression of DGKη reduces ERK 
phosphorylation.
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Figure 4.8.  DGKη reduces baseline and GPCR agonist-evoked phosphorylation of 
ERK. 
 A)  After serum-starvation (no serum) for 24 hours, HEK293 cells expressing RFP or 
RFP-DGKη were treated with vehicle, 10 µM carbachol, or 300 nM PMA for 5 minutes then 
were lysed.  20 µg of protein from each lysate was run on SDS-PAGE and blotted using anti-
phospho ERK and anti-ERK antibodies.  B)  Band intensities were quantified using ImageJ 
and pERK/ERK ratios were calculated.  Paired t tests were used to compare data.  *, p < 
0.05.  Data are the average of four experiments performed in duplicate.  All data are 
presented as means ± standard error.
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Figure 4.9.  Model showing how DGKη prolongs Gαq-coupled GPCR signaling. 
 A)  Activation of Gαq-coupled GPCRs leads to the stimulation of PLC-catalyzed 
hydrolysis of PIP2 and the release of IP3 and DAG.  IP3 activates IP3 receptors on the 
endoplasmic reticulum, resulting in the release of intracellular calcium stores.  Concurrently, 
DAG activates conventional and novel isoforms of PKC, leading to the phosphorylation of 
ERK by MAP kinase cascades.  Additionally, PKC activity leads to the phosphorylation of 
activated GPCRs, resulting in receptor desensitization and the attenuation of GPCR 
signaling.  B)  After receptor activation, overexpressed DGKη reduces the pool of free DAG 
by converting it into PA, thus suppressing the activation of PKC.  Decreased PKC activity 
leads to reduced phosphorylation of ERK.  As previously shown (173-176), reduced PKC 
activity attenuates GPCR desensitization.  This leads to prolonged IP3 and intracellular 
calcium release following receptor activation.
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DISCUSSION 
 Collectively, our data suggest a model for how DGKη prolongs GPCR signaling (Fig. 
4.9).  Stimulation of Gαq-coupled GPCRs leads to the activation of phospholipase C (PLC) 
and the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-
triphosphate (IP3) and DAG.  IP3 subsequently induces the release of endoplasmic reticulum 
calcium stores, raising the cytosolic concentration of Ca
2+.  In cells without DGKη activity 
(Fig. 4.9A), DAG activates PKC, leading to the phosphorylation and desensitization of the 
activated GPCR, followed by termination of GPCR signaling (170,173,174).  Activated PKC 
also signals through other downstream pathways, including MAPK cascades which 
culminate in ERK phosphorylation.  However, in cells overexpressing DGKη, DAG is 
phosphorylated to PA, leading to a decreased level of PKC activation (Fig. 4.9B, red).  This 
causes a decrease in the rate of GPCR phosphorylation and desensitization, resulting in 
prolonged GPCR signaling (as evidenced by sustained intracellular calcium release).  
Reduced PKC activity also leads to reduced activation of MAPK cascades, resulting in 
decreased phosphorylation of ERK. 
 We focused on PKCδ because it is highly expressed (177) and mediates ERK 
phosphorylation (154) in HEK293 cells, and because it preferentially activates GRK2, a 
regulator of GPCR signaling (171).  Moreover, PKCδ is a Ca2+-insensitive isoform of PKC 
(30), and thus would not be affected by prolonged calcium responses.   
During activation, PKC isoforms translocate to the plasma membrane (178), and are 
autophosphorylated at multiple amino acid residues (179,180).  We attempted to measure 
PKC activation directly via: 1) PKCδ immunostaining (Fig. 4.7A), 2) membrane/cytosol 
fractionation and PKCδ western blotting (181), 3) anti-phospho-PKCδ western blotting 
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(182), 4) anti-pan-phospho-PKC western blotting (183), and 5) a FRET biosensor of PKC 
activity (184).  Unfortunately, we did not observe endogenous PKC activation with any of 
these techniques after stimulation of endogenous receptors with carbachol, and were 
therefore unable to measure the effect of DGKη on endogenous PKC activity.  This did not 
reflect technical limitations, as we did observe endogenous PKCδ activation after direct 
stimulation with PMA (Fig. 4.7A).  Instead, our inability to directly measure endogenous 
PKC activity suggests very little PKC is activated when endogenous receptors are stimulated.  
Indeed, previous studies that measured PKC activity employed overexpressed receptors 
(181,183).  It is well-documented that overexpressed receptors activate signaling pathways at 
non-physiological (excessive) levels relative to endogenous receptor activation (185).  This is 
precisely why we used endogenous M3 receptors and a sub-EC50 concentration of carbachol 
(154) in our signaling experiments, to probe potential negative and positive modulation at 
physiological levels of GPCR activation. 
Alternatively, it is possible that 10 µM carbachol selectively stimulates the strong 
activation of a single PKC isoform other than PKCδ, which does not phosphorylate either 
itself or the PKC biosensor.  However, it is far more likely that stimulation of endogenous M3 
receptors in HEK293 cells simply results in a very low level of DAG release and PKC 
activation.  Indeed, only a minimal level of DGKη expression results in the full DGKη-
mediated signaling effect (Fig. 4.2E), consistent with a very small amount of available 
substrate.  Nevertheless, modulation of PKC activity clearly mediates the effect of DGKη on 
GPCR signaling, as both activation (Fig. 4.7B) and depletion (Fig. 4.7D) of PKC blocks 
overexpressed DGKη from prolonging endogenous M3 receptor activation.  Furthermore, 
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after signal amplification downstream of PKC by the Raf-MEK-ERK cascade, activation by 
10 µM carbachol and suppression by DGKη were observed (Fig. 4.8B). 
 It is well-established that PKC activation leads to desensitization of GPCRs 
(170,173,174).  Based on this literature, we propose that overexpression of DGKη prolongs 
GPCR signaling by attenuating PKC-mediated phosphorylation and desensitization of 
GPCRs (Fig. 4.9).  Such a mechanism should have a greater effect on the duration of calcium 
responses than the intensity, as we observed (Fig. 4.1 E,F).  Likewise, cholinergic stimulation 
of cells expressing a phosphorylation-deficient M3 receptor resulted in prolonged calcium 
mobilization compared to cells expressing wild-type M3 receptor (186), strongly resembling 
the effect of overexpressed DGKη on the M3 receptor.  Although PKC directly 
phosphorylates some GPCRs (44,170), phosphorylation of the M3 receptor in HEK293 cells 
is likely indirect, through the activation of G protein-coupled receptor kinases (GRKs).  In 
HEK293 cells, M3 receptor activity is regulated by GRKs 2, 3, and 6 (154), at least one of 
which is activated by PKC (171,187,188).  Interestingly, GRK3 is also genetically linked to 
BPD (150), suggesting that dysregulation of GPCR signaling is important in the pathology of 
BPD.   
 Like DGKη, other DGK isoforms regulate PKC and receptor signaling.  For example, 
disruption of the gene encoding DGKδ leads to DAG accumulation, enhanced PKC activity 
and EGFR phosphorylation (189), culminating in a PKC-dependent increase in EGFR 
ubiquitination and degradation (190).  DGKs also regulate inter-receptor desensitization 
pathways, as DGKθ attenuates bradykinin-evoked, PKC-mediated phosphorylation of EGFR, 
a phosphorylation event that is linked to EGFR desensitization (191).  Interestingly, EGFR is 
a receptor tyrosine kinase, indicating that regulation of receptor signaling by DGKs is not 
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limited to GPCRs.  Together with our study, it is clear that multiple members of the DGK 
enzyme family regulate PKC activity and receptor signaling. 
 Lastly, there are several connections between DGKη-regulated signaling pathways 
and BPD.  Patients with BPD show increased levels of PKC activity compared to unaffected 
controls, which can be inhibited by the mood stabilizers lithium and valproate (153,192-194).  
In fact, there is clinical interest in PKC inhibitors as treatments for BPD (195-199).  Based on 
our current study, increased DGKη activity should reduce PKC activity, suggesting that 
increased DGKη expression does not contribute to BPD simply by regulating global PKC 
activity.  The DGKη product PA is also a critical intermediate in the phosphatidylinositol 
cycle, another proposed therapeutic target of lithium (200-202).  Interestingly, three 
polymorphisms in the DGKη gene which are linked to BPD are not correlated with 
responsiveness to lithium therapy (203), although this does not rule out lithium-sensitive 
pathways in the role of DGKη in BPD.  Future studies are needed to delineate precisely how 
DGKη activity is altered in BPD patients and how alterations in DGKη levels affect PKC and 
GPCR signaling in neurons and in animal models of BPD. 
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CHAPTER 5:  CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Perhaps the most fundamental result to come out of my graduate work is the 
discovery that the physiologically relevant nucleotide AMP is an adenosine A1 receptor 
agonist (see Chapter 2).  AMP was previously known to have some signaling activity, 
primarily via stimulation of AMP-activated protein kinase, an important intracellular 
regulator of energy homeostasis (204).  However, prior to my work, an extracellular receptor 
for AMP was not believed to exist.  Indeed, AMP was thought of as the sole silent 
intermediate in an extracellular hydrolysis pathway in which both the upstream (ATP and 
ADP, which activate P2X and P2Y receptors) and downstream elements (adenosine, which 
activates adenosine receptors) had active signaling roles (75).  The fact that AMP activates 
the A1 receptor independent of hydrolysis to adenosine, considering the biological ubiquity 
of AMP, necessitates a fundamental reevaluation of A1R-mediated signaling. 
 For example, one area in which AMP activity through the A1 receptor may be 
important is in the regulation of sleep and hibernation.  Circulating AMP concentration varies 
in a circadian fashion and is elevated in mice exposed to continuous darkness (82).  
Intraperitoneal injection of AMP also induces a hypothermic state similar to torpor, although 
there is some disagreement as to whether this state reflects true torpor (205).  Strikingly, 
intraventricular injection of a selective A1R agonist induces torpor and injection of an A1R 
antagonist reverses spontaneous torpor in the arctic ground squirrel, a hibernating mammal 
(206).  Furthermore, central administration of a selective A1R agonist induces a similar 
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torpor-like state in rats (127), a non-hibernating mammal.  These studies indicate that both 
circulating AMP levels and A1R activity in the CNS are very important in mediating 
hypothermic metabolic states during torpor or hibernation.  Thus, it is possible that AMP 
signaling through A1R may play a role in this metabolic regulation. 
 Clearly, future studies are needed to delineate the biological functions of AMP and 
adenosine signaling through the A1 receptor.  However, there is reason to believe that such 
studies may be very difficult to perform.  In vivo signaling environments are significantly 
more complex than the highly controlled systems used to evaluate adenosine receptor 
signaling in Chapter 2.  Multiple, redundant enzymes which hydrolyze AMP to adenosine 
exist in vivo, including three (PAP, NT5E, and tissue-nonspecific alkaline phosphatase) in 
the dorsal root ganglia alone (207), which will hamper the use of genetic approaches.  
Likewise, a lack of known inhibitors for all such enzymes, as well as bioavailability/delivery 
concerns will limit the effectiveness of pharmacological inhibition strategies.  Thus, even 
using a combination of genetic and pharmacological approaches the complete elimination of 
AMP hydrolysis in a biologically relevant setting may prove to be an impossible task.  
Indeed, due to the ubiquity of both AMP and adenosine, even accurately evaluating the 
degree to which enzymatic hydrolysis of AMP has been abolished would be very difficult.  
Furthermore, extracellular adenosine is primarily generated via AMP hydrolysis (75), and 
also activates A2A, A2B and A3 receptors, so even with the complete elimination of 
extracellular AMP hydrolysis, changes in A2AR-, A2BR-, and A3R-mediated signaling due to 
decreases in adenosine would complicate the analysis of A1R signaling. 
 Nevertheless, clever experimental design may allow the biological signaling roles of 
adenosine and AMP to be teased apart.  For example, one promising experiment entails the 
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creation of a knockin mouse expressing an AMP-insensitive A1 receptor in place of wild-type 
A1R.  Specifically, this mouse would express a receptor in which the residue homologous to 
histidine 251 is mutated to alanine, as in Figure 2.11.  Despite the A1 receptor’s ubiquitous 
expression and importance in regulation of the cardiovascular system, A1R knockout mice 
are completely viable and have been used for various behavioral studies (70,76,108,109).  
Thus, it is likely that a knockin mouse expressing a mutated A1 receptor would survive as 
well.  The A1 receptors expressed by this mouse should be resistant to activation by AMP, 
but should retain wild-type sensitivity towards adenosine (Fig. 2.11).  Therefore, these mice 
should exhibit a systemic lack of extracellular AMP signaling, but unaffected adenosine 
signaling.  Phenotypic analysis of these mice – evaluation of sleep behavior/circadian 
rhythms, cardiovascular function, or nociceptive behavior, for example – and comparison to 
wild-type mice should lead to a better understanding of the biological roles of AMP signaling 
through the A1 receptor. 
 During my graduate work, I also discovered that AMP preferentially activates Gαi 
over Gαq through A1R (Fig. 2.6, Fig. 3.2), one of the first known instances of functional 
selectivity by an endogenous signaling molecule.  Functional selectivity has been heavily 
studied in recent years, with a particular focus on the potential of functionally selective 
compounds in drug design (35,119).  Nevertheless, very little work has been done to examine 
functional selectivity in the context of endogenous signaling.  The physiological trace amine 
N,N-dimethyltryptamine (DMT) stimulates calcium mobilization downstream of the 5-HT2A 
serotonin receptor with an efficacy approximately 25% of that of serotonin itself (208).  
However, this may not be functional selectivity per se, as the efficacies of serotonin and 
DMT at 5-HT2AR have not been compared via other downstream signaling pathways (i.e. 
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DMT could simply be a universally low-efficacy agonist).  Furthermore, DMT is only 
present in vivo in very small amounts, so the biological relevance of this activity is suspect.  
Additionally, discrepancies in the efficacy of the endogenous cannabinoid receptor agonist 
anandamide have been observed by different groups when measuring different downstream 
signaling pathways (209), but these differences have not been rigorously confirmed in a 
single laboratory.  In contrast to these studies, AMP is known to be present in vivo in 
significant quantities (with concentrations regulated by light exposure and food 
consumption), and the differential efficacy of AMP was measured in two very similar 
signaling assays under identical conditions.  These results suggest that functional selectivity 
may have an important role in endogenous GPCR signaling. 
 A confounding problem in the investigation of the endogenous role of GPCR 
functional selectivity is the limited number of GPCRs that are known to have more than one 
physiological ligand.  This complicates the analysis of functional selectivity by preventing 
comparisons between endogenous ligands, thus necessitating the use of synthetic ligands to 
define ‘full agonist’ activity (which may or may not be accurate, particularly if only a few 
synthetic agonists have been developed for a given receptor).  For example, the 5-HT1A, 5-
HT2A, and 5-HT2C serotonin receptors are activated by both serotonin and DMT, a closely 
related compound (210,211).  However, as mentioned above, DMT is present at very low 
levels in most biological systems and thus has little relevance as an endogenous signaling 
molecule.  Additionally, some P2Y receptors (notably P2Y2) are sensitive to both adenine 
and uridine nucleotides (212), and the CB1 and CB2 cannabinoid receptors are activated by 
multiple endocannabinoid ligands, including anandamide and 2-arachidonoyl glycerol (213).  
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Lastly, the metabotropic glutamate receptor mGluR4 is sensitive to the protein metabolite 
phosphoserine as well as glutamate (214). 
 Nevertheless, the vast majority of GPCRs are either orphan receptors with no known 
ligand, or have exactly one known endogenous ligand.  To a great extent, the lack of known 
receptors with multiple biological ligands is simply due to a lack of investigation.  Despite 
the existence of many ligands which activate multiple receptors, it is largely assumed that 
each receptor is activated by a single ligand.  By this logic, if one biological ligand has been 
identified for a given receptor, there is no need to search for others.  Indeed, I assumed that 
this was true regarding the A1 receptor, until my serendipitous discovery that a second ligand 
did indeed exist. 
 High-throughput screening to identify ligands of orphan GPCRs has now been taking 
place for nearly two decades (215,216).  My discovery of a second endogenous A1R ligand, 
together with the studies discussed above, suggest that these screening efforts should be 
expanded considerably.  Notably, all of the agonist pairs (or families, in the case of the 
endocannabinoids) identified thus far that activate a single GPCR are chemically very 
similar, suggesting that the most profitable way to search for additional GPCR ligands is 
among biological compounds closely related to the known ligand.  Thus, any such 
structurally related candidate molecules should also be screened against GPCRs with known 
endogenous ligands, as part of or in addition to current orphan GPCR screening efforts.  
Furthermore, for the growing number of GPCRs at which multiple endogenous ligands have 
been identified, the functional selectivity of each ligand should be systematically evaluated 
using assays which measure as many downstream signaling pathways as possible. 
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 GPCRs are an absolutely fundamental part of eukaryotic cellular signaling.  Indeed, it 
is hard to overstate their importance in modern drug discovery and pharmacology: over 30% 
of currently marketed small-molecule drugs target GPCRs (2).  However, that is not to say 
that GPCR pharmacology is without its challenges.  Biological regulation of GPCR-
activating ligands is incredibly complex, and blanket stimulation or inhibition of GPCRs in 
vivo often has undesirable effects by interfering with endogenous signaling patterns.  This is 
especially true of GPCRs whose endogenous ligands are critical neurotransmitters or 
signaling molecules.  For example, serotonin receptor agonists have psychedelic effects and 
are of limited medical use, whereas serotonin reuptake inhibitors – which enhance available 
levels of serotonin after endogenous release, but have no activity at serotonin receptors 
themselves – have immense therapeutic value as antidepressants.  This problem can largely 
be addressed by drugs that do not activate or inhibit GPCRs, but adjust the signaling caused 
by endogenous ligands; that is to say, GPCR modulators. 
 One possibility is the development of drugs that directly modulate GPCR signaling by 
binding to a secondary (allosteric) binding site on the receptor.  Allosteric modulator binding 
alters receptor conformation in such a way that does not cause downstream signaling alone, 
but affects (either positively or negatively) the degree of downstream signaling that occurs 
when the receptor is activated by a true agonist.  The most well-known example of a drug 
class that has this mechanism is the anxiolytic/sedative benzodiazepines, which function as 
positive allosteric modulators of the GABAA receptor (217).  The phenomenon is also very 
important in physiological signaling, as the inhibitory neurotransmitter glycine is also a 
positive allosteric modulator of NMDA-type glutamate receptors (218).  However, most of 
the work on allosteric modulators thus far has focused on ion channels (219), although there 
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have been recent advances in the development of allosteric GPCR modulators (220).  
Notably, many ion channels have large extracellular domains with a great deal of exposed 
surface area, and altering ion channel pore size offers a simple mechanism for signal 
modulation.  Conversely, the vast majority of GPCRs (all except the small class C subfamily) 
have very small extracellular domains (221) and the nature of the conformational changes 
that would have the desired modulatory effects is very poorly understood, which may limit 
the development of allosteric GPCR modulators. 
 Thus, there is also great promise in targeting other proteins which regulate GPCR 
signaling for drug discovery.  As with direct GPCR modulators, this strategy may avoid the 
side effects that accompany direct activation or inhibition of GPCRs.  Furthermore, this 
strategy would allow for the modulation of multiple GPCRs simultaneously.  It is recognized 
that nonselective GPCR-targeting drugs (both agonists and antagonists) have been 
significantly more effective in the clinic than highly selective ones, particularly for 
psychological indications (222).  These drugs have been dubbed ‘magic shotguns’ (as 
opposed to more selective ‘magic bullets’), and drugs targeting GPCR modulators should 
benefit from a similar breadth of function.  Indeed, the receptor selectivity of drugs targeting 
GPCR modulators should be determined more by the tissue and cellular distribution of the 
modulators themselves, and not by GPCR family or structural similarity.  This may aid in the 
treatment of diseases in which dysregulated GPCR signaling is localized to a particular target 
tissue, but is not limited to a single receptor. 
 Fortunately for such drug discovery efforts, there are multiple protein families which 
are critical in the regulation of GPCRs, including most notably the G protein-coupled 
receptor kinase (GRK) family (223) and the arrestin family (224).  The regulator of G protein 
 131 
signaling (RGS) family is also important in the regulation of GPCR signaling, although RGS 
proteins do not modulate GPCRs themselves.  Instead, they enhance the GTPase activity of 
the associated Gα subunits, attenuating G protein signaling after GPCR activation (225).  My 
graduate work has added DGKη, a seemingly unrelated lipid kinase, to this list of GPCR-
modulating enzymes, and other DGK isoforms may have similar activity.  Indeed, drug 
discovery targeting members of any or all of these protein families may prove fruitful in the 
future.  However, arrestins and RGS proteins act solely via protein-protein interactions, and 
do not possess enzymatic activity.  This necessitates the development of protein-protein 
interaction inhibitors in order to affect arrestin or RGS function, which will make the 
discovery of effective compounds more difficult.  Thus, the catalytically active GRK and 
DGK families are likely to provide more attractive targets, particularly using current ligand 
discovery strategies. 
 More specifically, since DGKη catalytic activity positively modulates GPCR 
signaling (Fig. 4.2), DGKη inhibitors may have therapeutic potential, particularly for the 
treatment of bipolar disorder, where increased DGKη expression is already implicated (142).  
However, pharmacological inhibition of DGKη may selectively affect only certain DGKη-
mediated signaling pathways.  DGKη is a very large protein with multiple and varied 
interaction domains (PH, C1, coiled-coil, and SAM), and DGKη enhances ERK signaling 
downstream of EGFR activation via a scaffolding mechanism unrelated to catalytic activity 
(226).  In fact, modulation of EGFR activity by DGKη may be important in lung cancer, as 
DGKη depletion (as distinct from inhibition) reduced the growth of lung cancer cells and 
improved the efficacy of an EGFR inhibitor (146).  Pharmacological inhibition of DGKη will 
most likely only affect the catalytic activity of DGKη, and not affect its scaffolding 
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functions.  Thus, therapeutic DGKη inhibitors will be better suited towards pathologies 
where the catalysis-dependant modulation of GPCR signaling is likely to be important (such 
as bipolar disorder), than diseases in which the catalysis-independent modulation of EGFR 
signaling is likely to be important (such as cancer). 
 Among protein families whose members regulate GPCR signaling, the DGK family is 
very diverse, containing ten unique isoforms with highly divergent expression profiles, some 
of which have multiple splicing variants (130).  In contrast, the arrestin family contains only 
two non-visual isoforms, which are both widely expressed, and the GRK family contains five 
non-visual isoforms, three of which are widely expressed.  Therefore, the DGK family may 
prove to be an exceptionally good target for the development of GPCR-regulating 
therapeutics, as the existence of so many isoforms with dramatically different expression 
profiles lessens the chance that a specific inhibitor of a single DGK isoform will either have 
broad systemic side effects due to global DGK inhibition, or will prove ineffective due to 
enzymatic compensation by other DGK isoforms in the target tissue.  On the other hand, the 
existence of so many DGK isoforms may make the identification of a truly isoform-selective 
DGK inhibitor more difficult.  Regardless, GPCR-modulating enzymes in general, and the 
DGK family in particular, constitute a target class with a great deal of untapped potential for 
drug discovery in the future. 
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